{
  "CUV.AX": {
    "ticker": "CUV.AX",
    "company_type": "mature_profitable",
    "financial_metrics": {
      "market_cap": 634537344,
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "fund_family": "",
      "category": "",
      "quote_type": "EQUITY",
      "long_name": "Clinuvel Pharmaceuticals Limited",
      "business_summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PR\u00c9NUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.",
      "enterprise_value": 390938304,
      "ev_ebitda_multiple": 8.399,
      "total_revenue": 95017568,
      "net_income": 36172520,
      "current_revenue": "$95,017,568.00",
      "yearly_revenue_growth": 0.072,
      "quarterly_revenue_growth": 0,
      "calculated_annual_growth": 7.7561728673677885,
      "calculated_quarterly_growth": 0,
      "revenue_data_statements": {
        "quarterly_income_stmt": {},
        "annual_income_stmt": {
          "2025-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.29834,
            "Normalized EBITDA": 57197032.0,
            "Net Income From Continuing Operation Net Minority Interest": 36172518.0,
            "Reconciled Depreciation": 1181394.0,
            "Reconciled Cost Of Revenue": 15880248.0,
            "EBITDA": 57197032.0,
            "EBIT": 56015638.0,
            "Net Interest Income": 4967683.0,
            "Interest Expense": 4462838.0,
            "Interest Income": 9430521.0,
            "Normalized Income": 36172518.0,
            "Net Income From Continuing And Discontinued Operation": 36172518.0,
            "Diluted Average Shares": NaN,
            "Basic Average Shares": NaN,
            "Diluted EPS": NaN,
            "Basic EPS": NaN,
            "Net Income Common Stockholders": 36172518.0,
            "Net Income": 36172518.0,
            "Net Income Including Noncontrolling Interests": 36172518.0,
            "Net Income Continuous Operations": 36172518.0,
            "Tax Provision": 15380282.0,
            "Pretax Income": 51552800.0,
            "Other Income Expense": 851908.0,
            "Other Non Operating Income Expenses": 851908.0,
            "Net Non Operating Interest Income Expense": 4967683.0,
            "Interest Expense Non Operating": 4462838.0,
            "Interest Income Non Operating": 9430521.0,
            "Operating Income": 45733209.0,
            "Operating Expense": 33404113.0,
            "Other Operating Expenses": 5368626.0,
            "Depreciation Amortization Depletion Income Statement": 1181394.0,
            "Depreciation And Amortization In Income Statement": 1181394.0,
            "Depreciation Income Statement": 1181394.0,
            "Selling General And Administration": 26854093.0,
            "General And Administrative Expense": 26854093.0,
            "Salaries And Wages": 26854093.0,
            "Gross Profit": 79137322.0,
            "Cost Of Revenue": 15880248.0,
            "Total Revenue": 95017570.0,
            "Operating Revenue": 95017570.0
          },
          "2024-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.296822,
            "Normalized EBITDA": 56275596.0,
            "Net Income From Continuing Operation Net Minority Interest": 35636359.0,
            "Reconciled Depreciation": 1142326.0,
            "Reconciled Cost Of Revenue": 10081406.0,
            "EBITDA": 56275596.0,
            "EBIT": 55133270.0,
            "Net Interest Income": 2870579.0,
            "Interest Expense": 4454292.0,
            "Interest Income": 7324871.0,
            "Normalized Income": 35636359.0,
            "Net Income From Continuing And Discontinued Operation": 35636359.0,
            "Diluted Average Shares": 51054956.0,
            "Basic Average Shares": 49834035.0,
            "Diluted EPS": 0.698,
            "Basic EPS": 0.715,
            "Net Income Common Stockholders": 35636359.0,
            "Net Income": 35636359.0,
            "Net Income Including Noncontrolling Interests": 35636359.0,
            "Net Income Continuous Operations": 35636359.0,
            "Tax Provision": 15042619.0,
            "Pretax Income": 50678978.0,
            "Other Income Expense": -197442.0,
            "Other Non Operating Income Expenses": -197442.0,
            "Net Non Operating Interest Income Expense": 2870579.0,
            "Interest Expense Non Operating": 4454292.0,
            "Interest Income Non Operating": 7324871.0,
            "Operating Income": 48005841.0,
            "Operating Expense": 30091061.0,
            "Other Operating Expenses": 3923539.0,
            "Depreciation Amortization Depletion Income Statement": 1142326.0,
            "Depreciation And Amortization In Income Statement": 1142326.0,
            "Depreciation Income Statement": 1142326.0,
            "Selling General And Administration": 25025196.0,
            "General And Administrative Expense": 25025196.0,
            "Salaries And Wages": 25025196.0,
            "Gross Profit": 78096902.0,
            "Cost Of Revenue": 10081406.0,
            "Total Revenue": 88178308.0,
            "Operating Revenue": 88178308.0
          },
          "2023-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.328534,
            "Normalized EBITDA": 49560844.0,
            "Net Income From Continuing Operation Net Minority Interest": 30604566.0,
            "Reconciled Depreciation": 789408.0,
            "Reconciled Cost Of Revenue": 8789521.0,
            "EBITDA": 49560844.0,
            "EBIT": 48771436.0,
            "Net Interest Income": 713143.0,
            "Interest Expense": 3192713.0,
            "Interest Income": 3905856.0,
            "Normalized Income": 30604566.0,
            "Net Income From Continuing And Discontinued Operation": 30604566.0,
            "Diluted Average Shares": 51784376.0,
            "Basic Average Shares": 49410338.0,
            "Diluted EPS": 0.591,
            "Basic EPS": 0.619,
            "Net Income Common Stockholders": 30604566.0,
            "Net Income": 30604566.0,
            "Net Income Including Noncontrolling Interests": 30604566.0,
            "Net Income Continuous Operations": 30604566.0,
            "Tax Provision": 14974157.0,
            "Pretax Income": 45578723.0,
            "Other Income Expense": 763082.0,
            "Other Non Operating Income Expenses": 763082.0,
            "Net Non Operating Interest Income Expense": 713143.0,
            "Interest Expense Non Operating": 3192713.0,
            "Interest Income Non Operating": 3905856.0,
            "Operating Income": 44102498.0,
            "Operating Expense": 25429299.0,
            "Other Operating Expenses": 2073152.0,
            "Depreciation Amortization Depletion Income Statement": 789408.0,
            "Depreciation And Amortization In Income Statement": 789408.0,
            "Depreciation Income Statement": 789408.0,
            "Selling General And Administration": 22566739.0,
            "General And Administrative Expense": 22566739.0,
            "Salaries And Wages": 22566739.0,
            "Gross Profit": 69531797.0,
            "Cost Of Revenue": 8789521.0,
            "Total Revenue": 78321318.0,
            "Operating Revenue": 78321318.0
          },
          "2022-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.391669,
            "Normalized EBITDA": 37353098.0,
            "Net Income From Continuing Operation Net Minority Interest": 20878465.0,
            "Reconciled Depreciation": 757826.0,
            "Reconciled Cost Of Revenue": 10483808.0,
            "EBITDA": 37353098.0,
            "EBIT": 36595272.0,
            "Net Interest Income": -1830286.0,
            "Interest Expense": 2274357.0,
            "Interest Income": 444071.0,
            "Normalized Income": 20878465.0,
            "Net Income From Continuing And Discontinued Operation": 20878465.0,
            "Diluted Average Shares": 51807605.0,
            "Basic Average Shares": 49410338.0,
            "Diluted EPS": 0.403,
            "Basic EPS": 0.423,
            "Net Income Common Stockholders": 20878465.0,
            "Net Income": 20878465.0,
            "Net Income Including Noncontrolling Interests": 20878465.0,
            "Net Income Continuous Operations": 20878465.0,
            "Tax Provision": 13442450.0,
            "Pretax Income": 34320915.0,
            "Other Income Expense": 821152.0,
            "Other Non Operating Income Expenses": 821152.0,
            "Net Non Operating Interest Income Expense": -1830286.0,
            "Interest Expense Non Operating": 2274357.0,
            "Interest Income Non Operating": 444071.0,
            "Operating Income": 35330049.0,
            "Operating Expense": 19908435.0,
            "Other Operating Expenses": 1438971.0,
            "Depreciation Amortization Depletion Income Statement": 757826.0,
            "Depreciation And Amortization In Income Statement": 757826.0,
            "Depreciation Income Statement": 757826.0,
            "Selling General And Administration": 17711638.0,
            "General And Administrative Expense": 17711638.0,
            "Salaries And Wages": 17711638.0,
            "Gross Profit": 55238484.0,
            "Cost Of Revenue": 10483808.0,
            "Total Revenue": 65722292.0,
            "Operating Revenue": 65722292.0
          },
          "2021-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": NaN,
            "Tax Rate For Calcs": NaN,
            "Normalized EBITDA": NaN,
            "Net Income From Continuing Operation Net Minority Interest": NaN,
            "Reconciled Depreciation": NaN,
            "Reconciled Cost Of Revenue": NaN,
            "EBITDA": NaN,
            "EBIT": NaN,
            "Net Interest Income": NaN,
            "Interest Expense": NaN,
            "Interest Income": NaN,
            "Normalized Income": NaN,
            "Net Income From Continuing And Discontinued Operation": NaN,
            "Diluted Average Shares": 51091419.0,
            "Basic Average Shares": 49410338.0,
            "Diluted EPS": 0.484,
            "Basic EPS": 0.5,
            "Net Income Common Stockholders": NaN,
            "Net Income": NaN,
            "Net Income Including Noncontrolling Interests": NaN,
            "Net Income Continuous Operations": NaN,
            "Tax Provision": NaN,
            "Pretax Income": NaN,
            "Other Income Expense": NaN,
            "Other Non Operating Income Expenses": NaN,
            "Net Non Operating Interest Income Expense": NaN,
            "Interest Expense Non Operating": NaN,
            "Interest Income Non Operating": NaN,
            "Operating Income": NaN,
            "Operating Expense": NaN,
            "Other Operating Expenses": NaN,
            "Depreciation Amortization Depletion Income Statement": NaN,
            "Depreciation And Amortization In Income Statement": NaN,
            "Depreciation Income Statement": NaN,
            "Selling General And Administration": NaN,
            "General And Administrative Expense": NaN,
            "Salaries And Wages": NaN,
            "Gross Profit": NaN,
            "Cost Of Revenue": NaN,
            "Total Revenue": NaN,
            "Operating Revenue": NaN
          }
        },
        "quarterly_financial_stmt": {},
        "annual_financial_stmt": {
          "2025-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.29834,
            "Normalized EBITDA": 57197032.0,
            "Net Income From Continuing Operation Net Minority Interest": 36172518.0,
            "Reconciled Depreciation": 1181394.0,
            "Reconciled Cost Of Revenue": 15880248.0,
            "EBITDA": 57197032.0,
            "EBIT": 56015638.0,
            "Net Interest Income": 4967683.0,
            "Interest Expense": 4462838.0,
            "Interest Income": 9430521.0,
            "Normalized Income": 36172518.0,
            "Net Income From Continuing And Discontinued Operation": 36172518.0,
            "Diluted Average Shares": NaN,
            "Basic Average Shares": NaN,
            "Diluted EPS": NaN,
            "Basic EPS": NaN,
            "Net Income Common Stockholders": 36172518.0,
            "Net Income": 36172518.0,
            "Net Income Including Noncontrolling Interests": 36172518.0,
            "Net Income Continuous Operations": 36172518.0,
            "Tax Provision": 15380282.0,
            "Pretax Income": 51552800.0,
            "Other Income Expense": 851908.0,
            "Other Non Operating Income Expenses": 851908.0,
            "Net Non Operating Interest Income Expense": 4967683.0,
            "Interest Expense Non Operating": 4462838.0,
            "Interest Income Non Operating": 9430521.0,
            "Operating Income": 45733209.0,
            "Operating Expense": 33404113.0,
            "Other Operating Expenses": 5368626.0,
            "Depreciation Amortization Depletion Income Statement": 1181394.0,
            "Depreciation And Amortization In Income Statement": 1181394.0,
            "Depreciation Income Statement": 1181394.0,
            "Selling General And Administration": 26854093.0,
            "General And Administrative Expense": 26854093.0,
            "Salaries And Wages": 26854093.0,
            "Gross Profit": 79137322.0,
            "Cost Of Revenue": 15880248.0,
            "Total Revenue": 95017570.0,
            "Operating Revenue": 95017570.0
          },
          "2024-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.296822,
            "Normalized EBITDA": 56275596.0,
            "Net Income From Continuing Operation Net Minority Interest": 35636359.0,
            "Reconciled Depreciation": 1142326.0,
            "Reconciled Cost Of Revenue": 10081406.0,
            "EBITDA": 56275596.0,
            "EBIT": 55133270.0,
            "Net Interest Income": 2870579.0,
            "Interest Expense": 4454292.0,
            "Interest Income": 7324871.0,
            "Normalized Income": 35636359.0,
            "Net Income From Continuing And Discontinued Operation": 35636359.0,
            "Diluted Average Shares": 51054956.0,
            "Basic Average Shares": 49834035.0,
            "Diluted EPS": 0.698,
            "Basic EPS": 0.715,
            "Net Income Common Stockholders": 35636359.0,
            "Net Income": 35636359.0,
            "Net Income Including Noncontrolling Interests": 35636359.0,
            "Net Income Continuous Operations": 35636359.0,
            "Tax Provision": 15042619.0,
            "Pretax Income": 50678978.0,
            "Other Income Expense": -197442.0,
            "Other Non Operating Income Expenses": -197442.0,
            "Net Non Operating Interest Income Expense": 2870579.0,
            "Interest Expense Non Operating": 4454292.0,
            "Interest Income Non Operating": 7324871.0,
            "Operating Income": 48005841.0,
            "Operating Expense": 30091061.0,
            "Other Operating Expenses": 3923539.0,
            "Depreciation Amortization Depletion Income Statement": 1142326.0,
            "Depreciation And Amortization In Income Statement": 1142326.0,
            "Depreciation Income Statement": 1142326.0,
            "Selling General And Administration": 25025196.0,
            "General And Administrative Expense": 25025196.0,
            "Salaries And Wages": 25025196.0,
            "Gross Profit": 78096902.0,
            "Cost Of Revenue": 10081406.0,
            "Total Revenue": 88178308.0,
            "Operating Revenue": 88178308.0
          },
          "2023-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.328534,
            "Normalized EBITDA": 49560844.0,
            "Net Income From Continuing Operation Net Minority Interest": 30604566.0,
            "Reconciled Depreciation": 789408.0,
            "Reconciled Cost Of Revenue": 8789521.0,
            "EBITDA": 49560844.0,
            "EBIT": 48771436.0,
            "Net Interest Income": 713143.0,
            "Interest Expense": 3192713.0,
            "Interest Income": 3905856.0,
            "Normalized Income": 30604566.0,
            "Net Income From Continuing And Discontinued Operation": 30604566.0,
            "Diluted Average Shares": 51784376.0,
            "Basic Average Shares": 49410338.0,
            "Diluted EPS": 0.591,
            "Basic EPS": 0.619,
            "Net Income Common Stockholders": 30604566.0,
            "Net Income": 30604566.0,
            "Net Income Including Noncontrolling Interests": 30604566.0,
            "Net Income Continuous Operations": 30604566.0,
            "Tax Provision": 14974157.0,
            "Pretax Income": 45578723.0,
            "Other Income Expense": 763082.0,
            "Other Non Operating Income Expenses": 763082.0,
            "Net Non Operating Interest Income Expense": 713143.0,
            "Interest Expense Non Operating": 3192713.0,
            "Interest Income Non Operating": 3905856.0,
            "Operating Income": 44102498.0,
            "Operating Expense": 25429299.0,
            "Other Operating Expenses": 2073152.0,
            "Depreciation Amortization Depletion Income Statement": 789408.0,
            "Depreciation And Amortization In Income Statement": 789408.0,
            "Depreciation Income Statement": 789408.0,
            "Selling General And Administration": 22566739.0,
            "General And Administrative Expense": 22566739.0,
            "Salaries And Wages": 22566739.0,
            "Gross Profit": 69531797.0,
            "Cost Of Revenue": 8789521.0,
            "Total Revenue": 78321318.0,
            "Operating Revenue": 78321318.0
          },
          "2022-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": 0.0,
            "Tax Rate For Calcs": 0.391669,
            "Normalized EBITDA": 37353098.0,
            "Net Income From Continuing Operation Net Minority Interest": 20878465.0,
            "Reconciled Depreciation": 757826.0,
            "Reconciled Cost Of Revenue": 10483808.0,
            "EBITDA": 37353098.0,
            "EBIT": 36595272.0,
            "Net Interest Income": -1830286.0,
            "Interest Expense": 2274357.0,
            "Interest Income": 444071.0,
            "Normalized Income": 20878465.0,
            "Net Income From Continuing And Discontinued Operation": 20878465.0,
            "Diluted Average Shares": 51807605.0,
            "Basic Average Shares": 49410338.0,
            "Diluted EPS": 0.403,
            "Basic EPS": 0.423,
            "Net Income Common Stockholders": 20878465.0,
            "Net Income": 20878465.0,
            "Net Income Including Noncontrolling Interests": 20878465.0,
            "Net Income Continuous Operations": 20878465.0,
            "Tax Provision": 13442450.0,
            "Pretax Income": 34320915.0,
            "Other Income Expense": 821152.0,
            "Other Non Operating Income Expenses": 821152.0,
            "Net Non Operating Interest Income Expense": -1830286.0,
            "Interest Expense Non Operating": 2274357.0,
            "Interest Income Non Operating": 444071.0,
            "Operating Income": 35330049.0,
            "Operating Expense": 19908435.0,
            "Other Operating Expenses": 1438971.0,
            "Depreciation Amortization Depletion Income Statement": 757826.0,
            "Depreciation And Amortization In Income Statement": 757826.0,
            "Depreciation Income Statement": 757826.0,
            "Selling General And Administration": 17711638.0,
            "General And Administrative Expense": 17711638.0,
            "Salaries And Wages": 17711638.0,
            "Gross Profit": 55238484.0,
            "Cost Of Revenue": 10483808.0,
            "Total Revenue": 65722292.0,
            "Operating Revenue": 65722292.0
          },
          "2021-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": NaN,
            "Tax Rate For Calcs": NaN,
            "Normalized EBITDA": NaN,
            "Net Income From Continuing Operation Net Minority Interest": NaN,
            "Reconciled Depreciation": NaN,
            "Reconciled Cost Of Revenue": NaN,
            "EBITDA": NaN,
            "EBIT": NaN,
            "Net Interest Income": NaN,
            "Interest Expense": NaN,
            "Interest Income": NaN,
            "Normalized Income": NaN,
            "Net Income From Continuing And Discontinued Operation": NaN,
            "Diluted Average Shares": 51091419.0,
            "Basic Average Shares": 49410338.0,
            "Diluted EPS": 0.484,
            "Basic EPS": 0.5,
            "Net Income Common Stockholders": NaN,
            "Net Income": NaN,
            "Net Income Including Noncontrolling Interests": NaN,
            "Net Income Continuous Operations": NaN,
            "Tax Provision": NaN,
            "Pretax Income": NaN,
            "Other Income Expense": NaN,
            "Other Non Operating Income Expenses": NaN,
            "Net Non Operating Interest Income Expense": NaN,
            "Interest Expense Non Operating": NaN,
            "Interest Income Non Operating": NaN,
            "Operating Income": NaN,
            "Operating Expense": NaN,
            "Other Operating Expenses": NaN,
            "Depreciation Amortization Depletion Income Statement": NaN,
            "Depreciation And Amortization In Income Statement": NaN,
            "Depreciation Income Statement": NaN,
            "Selling General And Administration": NaN,
            "General And Administrative Expense": NaN,
            "Salaries And Wages": NaN,
            "Gross Profit": NaN,
            "Cost Of Revenue": NaN,
            "Total Revenue": NaN,
            "Operating Revenue": NaN
          }
        },
        "cashflow": {
          "2025-06-30 00:00:00": {
            "Free Cash Flow": 40796897.0,
            "Repurchase Of Capital Stock": -440906.0,
            "Issuance Of Capital Stock": 189000.0,
            "Capital Expenditure": -298567.0,
            "Income Tax Paid Supplemental Data": 15725799.0,
            "End Cash Position": 28020655.0,
            "Beginning Cash Position": 35200751.0,
            "Effect Of Exchange Rate Changes": 2379200.0,
            "Changes In Cash": -9559296.0,
            "Financing Cash Flow": -2938626.0,
            "Cash Flow From Continuing Financing Activities": -2938626.0,
            "Net Other Financing Charges": -182701.0,
            "Interest Paid Cff": NaN,
            "Cash Dividends Paid": -2504019.0,
            "Common Stock Dividend Paid": -2504019.0,
            "Net Common Stock Issuance": -251906.0,
            "Common Stock Payments": -440906.0,
            "Common Stock Issuance": 189000.0,
            "Investing Cash Flow": -47716134.0,
            "Cash Flow From Continuing Investing Activities": -47716134.0,
            "Net Investment Purchase And Sale": -47417567.0,
            "Purchase Of Investment": -47417567.0,
            "Net PPE Purchase And Sale": -298567.0,
            "Purchase Of PPE": -298567.0,
            "Cash Flowsfromusedin Operating Activities Direct": 41095464.0,
            "Taxes Refund Paid Direct": -15725799.0,
            "Interest Received Direct": 7450313.0,
            "Classesof Cash Payments": -44447740.0,
            "Paymentsto Suppliersfor Goodsand Services": -44447740.0,
            "Classesof Cash Receiptsfrom Operating Activities": 93818690.0,
            "Other Cash Receiptsfrom Operating Activities": 2.0,
            "Receiptsfrom Government Grants": 24183.0,
            "Receiptsfrom Customers": 93794505.0
          },
          "2024-06-30 00:00:00": {
            "Free Cash Flow": 31477667.0,
            "Repurchase Of Capital Stock": -4909246.0,
            "Issuance Of Capital Stock": 4155010.0,
            "Capital Expenditure": -5576215.0,
            "Income Tax Paid Supplemental Data": 15648111.0,
            "End Cash Position": 35200751.0,
            "Beginning Cash Position": 31893021.0,
            "Effect Of Exchange Rate Changes": -1140419.0,
            "Changes In Cash": 4448149.0,
            "Financing Cash Flow": -3571807.0,
            "Cash Flow From Continuing Financing Activities": -3571807.0,
            "Net Other Financing Charges": -694688.0,
            "Interest Paid Cff": NaN,
            "Cash Dividends Paid": -2470227.0,
            "Common Stock Dividend Paid": -2470227.0,
            "Net Common Stock Issuance": -754236.0,
            "Common Stock Payments": -4909246.0,
            "Common Stock Issuance": 4155010.0,
            "Investing Cash Flow": -29033926.0,
            "Cash Flow From Continuing Investing Activities": -29033926.0,
            "Net Investment Purchase And Sale": -23457711.0,
            "Purchase Of Investment": -23457711.0,
            "Net PPE Purchase And Sale": -5576215.0,
            "Purchase Of PPE": -5576215.0,
            "Cash Flowsfromusedin Operating Activities Direct": 37053882.0,
            "Taxes Refund Paid Direct": -15403964.0,
            "Interest Received Direct": 7633046.0,
            "Classesof Cash Payments": -39749125.0,
            "Paymentsto Suppliersfor Goodsand Services": -39749125.0,
            "Classesof Cash Receiptsfrom Operating Activities": 84573925.0,
            "Other Cash Receiptsfrom Operating Activities": 208594.0,
            "Receiptsfrom Government Grants": 344394.0,
            "Receiptsfrom Customers": 84020937.0
          },
          "2023-06-30 00:00:00": {
            "Free Cash Flow": 35884531.0,
            "Repurchase Of Capital Stock": NaN,
            "Issuance Of Capital Stock": NaN,
            "Capital Expenditure": -1027532.0,
            "Income Tax Paid Supplemental Data": 7744922.0,
            "End Cash Position": 156813537.0,
            "Beginning Cash Position": 121509282.0,
            "Effect Of Exchange Rate Changes": 1659856.0,
            "Changes In Cash": 33644399.0,
            "Financing Cash Flow": -2240132.0,
            "Cash Flow From Continuing Financing Activities": -2240132.0,
            "Net Other Financing Charges": -527436.0,
            "Interest Paid Cff": NaN,
            "Cash Dividends Paid": -1976414.0,
            "Common Stock Dividend Paid": -1976414.0,
            "Net Common Stock Issuance": NaN,
            "Common Stock Payments": NaN,
            "Common Stock Issuance": NaN,
            "Investing Cash Flow": -1027532.0,
            "Cash Flow From Continuing Investing Activities": -1027532.0,
            "Net Investment Purchase And Sale": NaN,
            "Purchase Of Investment": NaN,
            "Net PPE Purchase And Sale": -1027532.0,
            "Purchase Of PPE": -1027532.0,
            "Cash Flowsfromusedin Operating Activities Direct": 36912063.0,
            "Taxes Refund Paid Direct": -7483999.0,
            "Interest Received Direct": 2727126.0,
            "Classesof Cash Payments": -33230793.0,
            "Paymentsto Suppliersfor Goodsand Services": -33230793.0,
            "Classesof Cash Receiptsfrom Operating Activities": 74899729.0,
            "Other Cash Receiptsfrom Operating Activities": NaN,
            "Receiptsfrom Government Grants": 22009.0,
            "Receiptsfrom Customers": 74877720.0
          },
          "2022-06-30 00:00:00": {
            "Free Cash Flow": 39437844.0,
            "Repurchase Of Capital Stock": NaN,
            "Issuance Of Capital Stock": NaN,
            "Capital Expenditure": -434438.0,
            "Income Tax Paid Supplemental Data": NaN,
            "End Cash Position": 121509282.0,
            "Beginning Cash Position": 82690982.0,
            "Effect Of Exchange Rate Changes": 884213.0,
            "Changes In Cash": 37934087.0,
            "Financing Cash Flow": -1503757.0,
            "Cash Flow From Continuing Financing Activities": -1503757.0,
            "Net Other Financing Charges": -536984.0,
            "Interest Paid Cff": NaN,
            "Cash Dividends Paid": -1235265.0,
            "Common Stock Dividend Paid": -1235265.0,
            "Net Common Stock Issuance": NaN,
            "Common Stock Payments": NaN,
            "Common Stock Issuance": NaN,
            "Investing Cash Flow": -434438.0,
            "Cash Flow From Continuing Investing Activities": -434438.0,
            "Net Investment Purchase And Sale": NaN,
            "Purchase Of Investment": NaN,
            "Net PPE Purchase And Sale": -434438.0,
            "Purchase Of PPE": -434438.0,
            "Cash Flowsfromusedin Operating Activities Direct": 39872282.0,
            "Taxes Refund Paid Direct": 358687.0,
            "Interest Received Direct": 248999.0,
            "Classesof Cash Payments": -27352186.0,
            "Paymentsto Suppliersfor Goodsand Services": -27352186.0,
            "Classesof Cash Receiptsfrom Operating Activities": 66616782.0,
            "Other Cash Receiptsfrom Operating Activities": NaN,
            "Receiptsfrom Government Grants": 217258.0,
            "Receiptsfrom Customers": 66399524.0
          },
          "2021-06-30 00:00:00": {
            "Free Cash Flow": NaN,
            "Repurchase Of Capital Stock": NaN,
            "Issuance Of Capital Stock": NaN,
            "Capital Expenditure": NaN,
            "Income Tax Paid Supplemental Data": NaN,
            "End Cash Position": NaN,
            "Beginning Cash Position": NaN,
            "Effect Of Exchange Rate Changes": NaN,
            "Changes In Cash": NaN,
            "Financing Cash Flow": NaN,
            "Cash Flow From Continuing Financing Activities": NaN,
            "Net Other Financing Charges": NaN,
            "Interest Paid Cff": -44405.0,
            "Cash Dividends Paid": NaN,
            "Common Stock Dividend Paid": NaN,
            "Net Common Stock Issuance": NaN,
            "Common Stock Payments": NaN,
            "Common Stock Issuance": NaN,
            "Investing Cash Flow": NaN,
            "Cash Flow From Continuing Investing Activities": NaN,
            "Net Investment Purchase And Sale": NaN,
            "Purchase Of Investment": NaN,
            "Net PPE Purchase And Sale": NaN,
            "Purchase Of PPE": NaN,
            "Cash Flowsfromusedin Operating Activities Direct": NaN,
            "Taxes Refund Paid Direct": NaN,
            "Interest Received Direct": NaN,
            "Classesof Cash Payments": NaN,
            "Paymentsto Suppliersfor Goodsand Services": NaN,
            "Classesof Cash Receiptsfrom Operating Activities": NaN,
            "Other Cash Receiptsfrom Operating Activities": 99359.0,
            "Receiptsfrom Government Grants": NaN,
            "Receiptsfrom Customers": NaN
          }
        },
        "annual_revenue": {
          "2025-06-30 00:00:00": 95017570.0,
          "2024-06-30 00:00:00": 88178308.0,
          "2023-06-30 00:00:00": 78321318.0,
          "2022-06-30 00:00:00": 65722292.0
        },
        "recent_annual_growth": 7.7561728673677885,
        "current_revenue": 95017568,
        "revenue_growth": 0.072,
        "quarterly_revenue_growth": 0
      },
      "free_cash_flow": 40796897.0,
      "total_debt": 528528,
      "total_cash": 224105936,
      "shares_outstanding": 50200740,
      "current_price": 12.64,
      "beta": 0.896,
      "pe_ratio": 17.555555,
      "pb_ratio": 2.631141,
      "ps_ratio": 6.6781054,
      "peg_ratio": null,
      "roe": 0.16301,
      "roa": 0.11374,
      "debt_to_equity": 0.00219,
      "current_ratio": 9.664,
      "revenue_growth": 0.072,
      "earnings_growth": -0.105,
      "dividend_yield": 0.41,
      "payout_ratio": 0.0696,
      "profit_margin": 38.068999999999996,
      "quick_ratio": 9.245,
      "book_value_per_share": 4.804,
      "cash_per_share": 4.471,
      "fifty_two_week_high": 14.0,
      "fifty_two_week_low": 9.41
    },
    "quality_score": {
      "quality_score": 80,
      "grade": "A",
      "data_quality": "High",
      "missing_penalty": 0
    },
    "analyses": {
      "competitive_position": {
        "method": "Competitive Position Analysis",
        "applicable": true,
        "overall_position_score": 4.1,
        "competitive_strength": "Weak",
        "market_share_estimate": 0.01,
        "position_trend": "Stable",
        "key_differentiators": [
          "Regulatory Barriers"
        ],
        "competitive_advantages": [
          "Financial Performance",
          "Regulatory Barriers"
        ],
        "competitive_threats": [
          "Capital Requirements"
        ],
        "strategic_risks": [],
        "confidence": "Medium",
        "recommendation": "Hold",
        "analysis_type": "competitive_position",
        "current_price": 12.64
      },
      "management_quality": {
        "method": "Management Quality Analysis",
        "applicable": true,
        "overall_quality_score": 7.0,
        "management_quality": "Good",
        "governance_risk": "High",
        "executive_count": 5,
        "insider_ownership": 0.16664,
        "strengths": [
          "Optimal insider ownership alignment"
        ],
        "concerns": [
          "High governance risk requires attention"
        ],
        "key_insights": [
          "Leadership team of 5 key executives identified",
          "Average executive compensation: $1,624,318"
        ],
        "confidence": "Medium",
        "recommendation": "Buy",
        "analysis_type": "management_quality",
        "current_price": 12.64
      },
      "analyst_consensus": {
        "method": "Professional Analyst Consensus",
        "applicable": true,
        "current_price": 12.64,
        "predicted_price": 24.53143,
        "target_high": 41.85,
        "target_low": 14.0,
        "upside_downside_pct": 94.07776898734177,
        "recommendation": "Hold",
        "recommendation_mean": null,
        "num_analysts": 7,
        "confidence": "Medium",
        "analysis_type": "analyst_consensus"
      },
      "technical": {
        "method": "Technical Analysis",
        "current_price": 12.64,
        "predicted_price": 18.081301080276063,
        "price_targets": {
          "short_term": 15.360650711799408,
          "medium_term": 18.081301080276063,
          "support_level": 8.896521685738486
        },
        "recommendation": "Hold",
        "ma_20": 12.68899998664856,
        "ma_50": 11.887800045013428,
        "ma_200": 11.363205933570862,
        "trend": "Strong Uptrend",
        "volatility_annual": 0.43048264154737537,
        "high_52w": 13.932691990297155,
        "low_52w": 9.364759669198406,
        "distance_from_high": -0.09278118312488658,
        "distance_from_low": 0.34974102804762075,
        "volume_trend": "Average Daily Volume:125348.55511811023, Trend: Below Average",
        "rsi_14": 53.73305977867797,
        "macd_line": 0.12744704243532468,
        "macd_signal": 0.21886269881475826,
        "macd_histogram": -0.09141565637943358,
        "bb_upper": 13.238368792523374,
        "bb_lower": 12.139631180773744,
        "stoch_k": 30.805267292032095,
        "stoch_d": 30.76256341422726,
        "technical_signals": {
          "recommendation": "Hold",
          "bullish_signals": 3,
          "bearish_signals": 4,
          "net_signal": -1,
          "signal_details": [
            "Strong MA uptrend",
            "RSI bearish zone",
            "MACD bearish crossover",
            "MACD histogram negative"
          ]
        },
        "chart_data": {
          "prices": [
            12.989999771118164,
            12.90999984741211,
            12.760000228881836,
            12.289999961853027,
            12.75,
            12.579999923706055,
            12.880000114440918,
            12.600000381469727,
            13.229999542236328,
            12.779999732971191,
            13.119999885559082,
            12.779999732971191,
            12.859999656677246,
            12.520000457763672,
            12.460000038146973,
            12.710000038146973,
            12.430000305175781,
            12.229999542236328,
            12.260000228881836,
            12.640000343322754
          ],
          "dates": [
            "12/09",
            "12/10",
            "12/11",
            "12/12",
            "12/15",
            "12/16",
            "12/17",
            "12/18",
            "12/19",
            "12/22",
            "12/23",
            "12/24",
            "12/29",
            "12/30",
            "12/31",
            "01/02",
            "01/05",
            "01/06",
            "01/07",
            "01/08"
          ]
        },
        "analysis_type": "technical"
      },
      "dcf": {
        "method": "DCF Analysis",
        "applicable": true,
        "predicted_price": 21.63923862417696,
        "current_price": 12.64,
        "upside_downside_pct": 71.19650810266582,
        "total_equity_value": 1086305791.9702654,
        "confidence": "Medium",
        "valuation": "Undervalued",
        "recommendation": "Strong Buy",
        "dcf_calculations": {
          "wacc": 0.07595497410670633,
          "cost_equity": 0.07602616000000001,
          "ev_ebitda_multiple": 8.399,
          "ev_ebitda_multiple_used": 8.399,
          "fcf_cagr": 0.011357398261176765,
          "ebitda_cagr": 0.13548502119939684,
          "fcf_future": 43166855.22953652,
          "ebitda_future": 107964391.50377572,
          "terminal_value_pg": 1090897897.9247937,
          "terminal_value_ebitda_multiple": 906792924.2402122,
          "average_terminal_value": 998845411.082503,
          "adjusted_terminal_value": 998845411.082503,
          "terminal_adjustment_factor": 1.0,
          "projected_free_cash_flows": [
            41260243.607049204,
            41728852.62604764,
            42202783.82430361,
            42682097.64792658,
            43166855.22953652
          ],
          "present_value_free_cash_flows": [
            38347555.98514225,
            36045267.1200366,
            33881201.77093398,
            31847061.352602176,
            29935045.505572945
          ],
          "pv_fcf": 170056131.73428798,
          "pv_terminal_value": 692672252.2359774,
          "enterprise_value": 862728383.9702654,
          "adjusted_debt": -223577408,
          "equity_value": 1086305791.9702654,
          "share_price": 21.63923862417696,
          "ticker_symbol": "CUV.AX",
          "last_close_price": 12.26,
          "confidence": "Medium",
          "terminal_ratio": 0.8545162911458813
        },
        "parameters_used": {
          "max_cagr": "30.0%",
          "terminal_growth": "3.5%",
          "sector": "Healthcare",
          "industry": "Biotechnology",
          "quality_adjustment": "A",
          "valuation_discount": null
        },
        "analysis_type": "dcf"
      },
      "ai_insights": {
        "method": "AI Insights Analysis",
        "applicable": true,
        "current_price": 12.64,
        "predicted_price": 12.64,
        "recommendation": "Hold",
        "confidence": "High",
        "ai_insights": {
          "market_position": "Moderate",
          "growth_prospects": "Moderate",
          "competitive_advantage": "Moderate",
          "management_quality": "Good",
          "industry_outlook": "Positive",
          "key_strengths": [
            "Specialized focus on rare skin disorders, providing a niche market with less competition",
            "Growing revenue with a 7.2% growth rate, indicating a stable financial foundation"
          ],
          "key_risks": [
            "Dependence on a limited number of products, making the company vulnerable to regulatory or market changes",
            "High research and development costs associated with biotechnology, potentially impacting profitability"
          ],
          "ai_method": "LLM"
        },
        "revenue_trends": {
          "trend_assessment": "Moderate Growth",
          "growth_rate": 7.2,
          "growth_consistency": "Consistent",
          "future_outlook": "Positive",
          "ai_method": "LLM"
        },
        "market_analysis": {
          "market_cap_category": "Small Cap",
          "sector": "Healthcare",
          "industry": "Biotechnology",
          "beta": 0.896
        },
        "ai_methods_used": {
          "insights": "LLM",
          "revenue_trends": "LLM"
        },
        "risk_factors": [],
        "analysis_type": "ai_insights"
      },
      "comparable": {
        "method": "Comparable Analysis",
        "applicable": true,
        "target_multiples": {
          "pe": 49.50000000000001,
          "ps": 13.200000000000001,
          "pb": 4.4,
          "ev_ebitda": 27.500000000000004
        },
        "fair_values": {
          "pe_fair_value": 35.66759653343756,
          "ps_fair_value": 24.98433086046142
        },
        "predicted_price": 30.32596369694949,
        "current_price": 12.64,
        "upside_downside_pct": 139.92059886827127,
        "recommendation": "Strong Buy",
        "confidence": "Medium",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "parameters_used": {
          "pe_multiple": "49.5x",
          "ps_multiple": "13.2x",
          "quality_adjustment": "A"
        },
        "peer_tickers": [
          "GILD",
          "AMGN",
          "BIIB",
          "REGN"
        ],
        "peer_averages": {
          "pe_ratio": 20.54413525,
          "ps_ratio": 4.7963272,
          "pb_ratio": 7.6247058,
          "ev_ebitda": 13.1585,
          "roe": 0.3672775075,
          "profit_margin": 0.2386675025
        },
        "current_multiples": {
          "pe_ratio": 17.555555,
          "ps_ratio": 6.6781054,
          "pb_ratio": 2.631141,
          "ev_ebitda": 8.399,
          "roe": 0.16301,
          "profit_margin": 0.38069
        },
        "relative_position": {
          "pe_ratio": "Discount",
          "ps_ratio": "Premium",
          "pb_ratio": "Discount",
          "ev_ebitda": "Discount",
          "roe": "Below",
          "profit_margin": "Superior"
        },
        "peer_insights": [
          "Trading at discount to peer group",
          "Underperforming peers on profitability"
        ],
        "analysis_type": "comparable"
      },
      "business_model": {
        "method": "Business Model Analysis",
        "applicable": true,
        "business_model_type": "Manufacturing",
        "primary_revenue_stream": "Mixed",
        "revenue_quality": "Fair",
        "recurring_percentage": 0.0,
        "scalability_score": 4.0,
        "growth_consistency": null,
        "strengths": [
          "Strong innovation capabilities drive competitive advantage"
        ],
        "risks": [
          "Low recurring revenue creates earnings volatility",
          "Concentrated product portfolio increases market risk",
          "Competitive threat: Increasing competition from generic or biosimilar products",
          "Competitive threat: Rapidly evolving regulatory landscape and potential changes to reimbursement policies"
        ],
        "competitive_moat": "Weak to Moderate - Scale and brand advantages",
        "confidence": "Medium",
        "recommendation": "Hold",
        "product_portfolio": {
          "product_breadth": "Narrow",
          "product_depth": "Deep",
          "core_products": [
            "SCENESSE",
            "PEDESSEN"
          ],
          "innovation_level": "High",
          "cross_selling_potential": "Low",
          "product_strengths": [
            "First-in-class drug for EPP",
            "Orphan drug designation"
          ],
          "product_weaknesses": [
            "Limited product pipeline",
            "Dependence on single product for revenue"
          ],
          "data_source": "LLM Analysis Only"
        },
        "competitive_differentiation": {
          "differentiation_strategy": "Differentiation",
          "competitive_advantages": [
            "Specialized expertise in photoprotective and repigmentation therapies",
            "Strong clinical trial results and regulatory approvals for SCENESSE and PEDESSEN",
            "Growing global presence and partnerships in key markets"
          ],
          "unique_value_propositions": [
            "First-in-class photoprotective therapy for erythropoietic protoporphyria (EPP) with SCENESSE",
            "Innovative repigmentation treatment for vitiligo with PEDESSEN"
          ],
          "key_competitors": [
            "Galderma Laboratories",
            "Janssen Pharmaceuticals",
            "Novartis Pharmaceuticals"
          ],
          "competitive_positioning": "Niche",
          "barriers_to_entry": [
            "High regulatory hurdles for new biotechnology products",
            "Significant investment required for research and development"
          ],
          "switching_costs": "Moderate",
          "brand_strength": "Moderate",
          "technology_moat": "Moderate",
          "distribution_advantages": [
            "Established relationships with specialty pharmacies and distributors",
            "Growing online presence and patient support programs"
          ],
          "competitive_threats": [
            "Increasing competition from generic or biosimilar products",
            "Rapidly evolving regulatory landscape and potential changes to reimbursement policies"
          ]
        },
        "segment_revenue_data": {
          "primary_segments": [
            {
              "segment_name": "SCENESSE Revenue",
              "revenue_percentage": 85.0,
              "growth_trend": "Growing",
              "margin_profile": "High"
            },
            {
              "segment_name": "Other Revenue",
              "revenue_percentage": 10.0,
              "growth_trend": "Stable",
              "margin_profile": "Medium"
            },
            {
              "segment_name": "Research and Development Grants",
              "revenue_percentage": 5.0,
              "growth_trend": "Declining",
              "margin_profile": "Low"
            }
          ],
          "revenue_diversification": "Low",
          "fastest_growing_segment": "SCENESSE Revenue",
          "largest_segment": "SCENESSE Revenue",
          "segment_risks": [
            "Regulatory Risks",
            "Competition from Generic Drugs",
            "Clinical Trial Failures"
          ],
          "cross_segment_synergies": [
            "Combination of SCENESSE with other treatments",
            "Leveraging research grants to develop new products"
          ]
        },
        "sec_edgar_data": {
          "ticker": "CUV.AX",
          "data_available": false
        },
        "analysis_type": "business_model",
        "current_price": 12.64
      },
      "news_sentiment": {
        "method": "News Sentiment Analysis",
        "applicable": true,
        "overall_sentiment_score": 0.16,
        "sentiment_rating": "Neutral",
        "news_count": 5,
        "recent_news": [
          {
            "title": "Artrya And 2 Other High Growth Tech Stocks With Potential In Australia",
            "summary": "As the Australian market kicks off 2026, the ASX has been relatively flat with a brief pause in the Santa Rally, while IT stocks have led declines amidst broader market uncertainties. In this environment, identifying high-growth tech stocks like Artrya and others requires careful consideration of their potential to navigate current challenges and capitalize on emerging opportunities within Australia's dynamic economic landscape.",
            "date": "2026-01-05",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/artrya-2-other-high-growth-193624679.html",
            "sentiment": "neutral",
            "sentiment_score": 0.0,
            "enhanced_facts": {
              "lead_fact": "Australian market kicks off 2026 with a relatively flat ASX and declines in IT stocks",
              "quantitative_evidence": "None",
              "business_mechanism": "Potential impact on CUV.AX's growth and navigation of current market challenges",
              "verbatim_quote": "None"
            }
          },
          {
            "title": "ASX Growth Stocks With High Insider Ownership December 2025",
            "summary": "As the Australian market approaches the end of 2025, it appears to be in a reflective mood with a slight dip as investors engage in profit-taking before the holiday break, despite Wall Street's indices nearing record highs. In this environment, growth companies with high insider ownership can present appealing opportunities due to their potential for alignment between management and shareholder interests.",
            "date": "2025-12-31",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/asx-growth-stocks-high-insider-193801717.html",
            "sentiment": "neutral",
            "sentiment_score": 0.0,
            "enhanced_facts": {
              "lead_fact": "Australian market experiences a slight dip as investors engage in profit-taking before the holiday break",
              "quantitative_evidence": "None",
              "business_mechanism": "Potential alignment between management and shareholder interests in growth companies with high insider ownership",
              "verbatim_quote": "None"
            }
          },
          {
            "title": "Exploring High Growth Tech Stocks in Australia Featuring Three Prominent Companies",
            "summary": "As the Australian market edges towards the holiday season, it is experiencing a slight dip, largely attributed to profit-taking as major global indices approach record highs. In this context, high growth tech stocks in Australia can offer intriguing opportunities for investors seeking innovation and potential expansion, particularly when these companies demonstrate resilience and adaptability amidst fluctuating economic conditions.",
            "date": "2025-12-30",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-193612686.html",
            "sentiment": "neutral",
            "sentiment_score": 0.0,
            "enhanced_facts": {
              "lead_fact": "Australian market experiencing a slight dip due to profit-taking as major global indices approach record highs",
              "quantitative_evidence": "None",
              "business_mechanism": "Potential impact on investor sentiment and market volatility for CUV.AX",
              "verbatim_quote": "None"
            }
          },
          {
            "title": "High Growth Tech Stocks To Watch In December 2025",
            "summary": "As the Australian market navigates a mixed landscape with tech stocks showing resilience amidst broader sector fluctuations, investors are keenly observing how economic indicators and global events influence small-cap performance. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to changing market dynamics.",
            "date": "2025-12-15",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-193606658.html",
            "sentiment": "neutral",
            "sentiment_score": 0.2,
            "enhanced_facts": {
              "lead_fact": "Australian market navigating a mixed landscape with tech stocks showing resilience",
              "quantitative_evidence": "None",
              "business_mechanism": "Potential increase in investor interest for high growth tech stocks like CUV.AX due to demonstrated resilience",
              "verbatim_quote": "None"
            }
          },
          {
            "title": "Clinuvel Pharmaceuticals (ASX:CUV) Is Up 6.2% After Expanding Singapore Peptide R&D Hub - Has The Bull Case Changed?",
            "summary": "Earlier in December 2025, CLINUVEL PHARMACEUTICALS LTD announced a major expansion of its VALLAURIX Research, Development and Innovation Centre in Singapore, backed by the Singapore Economic Development Board, to accelerate liquid controlled-release peptide drug development and integrate advanced formulation and analytical capabilities. This five-year investment is a core part of Clinuvel\u2019s vertical integration plan, positioning the Singapore hub as a global centre for next\u2011generation...",
            "date": "2025-12-11",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/clinuvel-pharmaceuticals-asx-cuv-6-050952814.html",
            "sentiment": "neutral",
            "sentiment_score": 0.6,
            "enhanced_facts": {
              "lead_fact": "Clinuvel Pharmaceuticals expands Singapore Peptide R&D Hub",
              "quantitative_evidence": "6.2% stock increase, five-year investment",
              "business_mechanism": "Accelerates liquid controlled-release peptide drug development and integrates advanced formulation and analytical capabilities, positioning the Singapore hub as a global centre for next-generation drug development",
              "verbatim_quote": "None available in the provided content"
            }
          }
        ],
        "key_developments": [],
        "sentiment_drivers": [
          "Positive coverage in 1 recent news items"
        ],
        "risk_factors": [],
        "overall_summary": [
          "The overall sentiment score of 0.16 is largely neutral, driven by a majority of articles with a sentiment score of 0.00, indicating a focus on informative content without strong emotional tone",
          "The few articles with positive sentiment scores, such as the one about Clinuvel Pharmaceuticals, suggest that specific company developments and expansions can drive positive market reactions and increase investor interest",
          "The generally low sentiment scores across the articles imply a lack of strong market enthusiasm or concern, potentially indicating a stable or waiting period for the high growth tech stocks in Australia",
          "Despite the neutral overall sentiment, the presence of some positive scores and the focus on high growth tech stocks suggest that there may be underlying optimism and potential for future growth in the Australian tech industry"
        ],
        "confidence": "Medium",
        "recommendation": "Hold",
        "analysis_type": "news_sentiment",
        "current_price": 12.64
      },
      "industry_analysis": {
        "method": "Enhanced Industry Analysis",
        "applicable": true,
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "recommendation": "Buy",
        "confidence": "Medium",
        "predicted_price": null,
        "industry_outlook": "Positive",
        "competitive_position": "Strong Player",
        "market_catalysts": [
          "**1. Increasing Scrutiny from Regulatory Bodies (Regulatory/Policy, 2024-2026)**",
          "**2. Implementation of Clinical Trials Regulation (CTR) (Regulatory/Policy, 2024-2026)**",
          "**3. Growing Demand for Personalized Medicine (Market/Economic, 2025-2030)**",
          "**4. Consolidation in the Biotechnology Sector (Industry-specific, 2025-2030)**",
          "**5. Growing Focus on Environmental Sustainability (ESG/Sustainability, 2025-2030)**",
          "**6. Advancements in Gene Editing Technologies (Technology/Innovation, 2025-2030)**",
          "**7. Growing Demand for Cancer Therapies (Market/Economic, 2025-2030)**"
        ],
        "porters_five_forces": {
          "supplier_power": {
            "level": "Medium",
            "factors": [
              "Standard suppliers"
            ],
            "score": 5
          },
          "buyer_power": {
            "level": "Medium",
            "factors": [
              "Diverse customers"
            ],
            "score": 5
          },
          "competitive_rivalry": {
            "level": "Medium",
            "factors": [
              "Industry competition"
            ],
            "score": 5
          },
          "threat_of_substitutes": {
            "level": "Medium",
            "factors": [
              "Alternative solutions"
            ],
            "score": 5
          },
          "barriers_to_entry": {
            "level": "Medium",
            "factors": [
              "Capital requirements"
            ],
            "score": 5
          },
          "overall_attractiveness": "Medium",
          "industry_profitability_outlook": "Stable"
        },
        "regulatory_risk": "Very High",
        "esg_score": 5.67,
        "market_size_estimate": "Small",
        "industry_growth_rate": 0.072,
        "industry_insights": {
          "outlook": "Positive",
          "outlook_reasoning": "The Biotechnology sector is expected to experience steady growth driven by increasing demand for innovative treatments, advancements in gene editing technologies, and growing investment in R&D. Key factors driving this assessment include the rising prevalence of chronic diseases, government initiatives to promote healthcare innovation, and the emergence of new business models in the sector. However, challenges such as regulatory hurdles, high R&D costs, and intense competition may temper growth prospects. Overall, the sector is poised for moderate growth over the next 5 years, with a compound annual growth rate (CAGR) of 7.2%.",
          "growth_drivers": [
            {
              "driver": "Advancements in Gene Editing Technologies",
              "explanation": "Gene editing technologies such as CRISPR/Cas9 are revolutionizing the treatment of genetic diseases, offering new avenues for therapeutic intervention and driving growth in the sector.",
              "timeline": "2025-2030",
              "magnitude": "High"
            },
            {
              "driver": "Increasing Demand for Innovative Treatments",
              "explanation": "The growing prevalence of chronic diseases such as cancer, diabetes, and Alzheimer's is driving demand for innovative treatments, creating opportunities for biotechnology companies to develop and commercialize new therapies.",
              "timeline": "2023-2028",
              "magnitude": "Medium"
            },
            {
              "driver": "Growing Investment in R&D",
              "explanation": "Increasing investment in R&D is driving innovation in the sector, enabling biotechnology companies to develop new products and therapies, and driving growth in the sector.",
              "timeline": "2025-2030",
              "magnitude": "High"
            }
          ],
          "headwinds": [
            {
              "headwind": "Regulatory Hurdles",
              "explanation": "Regulatory hurdles, including lengthy approval processes and stringent safety standards, can delay the commercialization of new therapies, impacting growth prospects in the sector.",
              "severity": "High",
              "mitigation": "Biotechnology companies can mitigate regulatory risks by engaging with regulatory agencies, conducting thorough clinical trials, and developing robust regulatory strategies."
            },
            {
              "headwind": "High R&D Costs",
              "explanation": "High R&D costs can limit the financial resources available to biotechnology companies, impacting their ability to invest in new product development and driving growth in the sector.",
              "severity": "Medium",
              "mitigation": "Biotechnology companies can mitigate R&D costs by optimizing their R&D processes, leveraging partnerships and collaborations, and exploring new funding models."
            },
            {
              "headwind": "Intense Competition",
              "explanation": "Intense competition in the sector can limit market share and drive down prices, impacting growth prospects in the sector.",
              "severity": "Medium",
              "mitigation": "Biotechnology companies can mitigate competitive risks by differentiating their products, developing strong brand identities, and leveraging strategic partnerships."
            }
          ],
          "market_size": "Large",
          "market_analysis": "The global biotechnology market is expected to reach $1.5 trillion by 2028, driven by increasing demand for innovative treatments, advancements in gene editing technologies, and growing investment in R&D. The market is characterized by a large addressable market, with opportunities for growth in both developed and emerging economies.",
          "maturity": "Growth",
          "maturity_reasoning": "The biotechnology sector is in the growth stage, driven by increasing demand for innovative treatments, advancements in gene editing technologies, and growing investment in R&D. Key factors supporting this assessment include the emergence of new business models, the growth of the global biotechnology market, and the increasing adoption of biotechnology products.",
          "cyclicality": "Medium",
          "cyclicality_analysis": "The biotechnology sector is moderately cyclical, driven by fluctuations in government funding, changes in regulatory policies, and shifts in consumer demand. Key factors influencing this assessment include the impact of economic downturns on government funding, the effect of regulatory changes on product approvals, and the influence of consumer preferences on product adoption.",
          "technology_disruption": "High",
          "technology_analysis": "The biotechnology sector is highly susceptible to technological disruption, driven by advancements in gene editing technologies, the growth of synthetic biology, and the increasing adoption of digital health technologies. Key factors supporting this assessment include the potential for gene editing technologies to revolutionize the treatment of genetic diseases, the emergence of new business models in synthetic biology, and the growing demand for digital health solutions.",
          "supply_demand_balance": "Balanced",
          "supply_demand_reasoning": "The biotechnology sector is characterized by a balanced supply-demand dynamic, driven by the growth of the global biotechnology market, the emergence of new business models, and the increasing adoption of biotechnology products. Key factors influencing this assessment include the impact of government funding on R&D investment, the effect of regulatory changes on product approvals, and the influence of consumer preferences on product adoption.",
          "pricing_power": "Moderate",
          "pricing_analysis": "The biotechnology sector is characterized by moderate pricing power, driven by the growth of the global biotechnology market, the emergence of new business models, and the increasing adoption of biotechnology products. Key factors influencing this assessment include the impact of competition on pricing, the effect of regulatory changes on product approvals, and the influence of consumer preferences on product adoption.",
          "capital_intensity": "High",
          "capital_analysis": "The biotechnology sector is highly capital-intensive, driven by the high costs of R&D, the need for significant investment in manufacturing and distribution, and the requirement for substantial funding to support product development and commercialization. Key factors influencing this assessment include the impact of government funding on R&D investment, the effect of regulatory changes on product approvals, and the influence of consumer preferences on product adoption.",
          "innovation_pace": "Rapid",
          "innovation_analysis": "The biotechnology sector is characterized by a rapid pace of innovation, driven by the growth of the global biotechnology market, the emergence of new business models, and the increasing adoption of biotechnology products. Key factors influencing this assessment include the impact of gene editing technologies on product development, the effect of synthetic biology on new product creation, and the influence of digital health technologies on product adoption.",
          "globalization_impact": "High",
          "globalization_analysis": "The biotechnology sector is highly susceptible to globalization, driven by the growth of the global biotechnology market, the emergence of new business models, and the increasing adoption of biotechnology products. Key factors influencing this assessment include the impact of international trade agreements on product approvals, the effect of regulatory changes on product approvals, and the influence of consumer preferences on product adoption.",
          "strategic_implications": "Key strategic insights and recommendations for companies in the biotechnology sector include: (1) investing in R&D to drive innovation and growth, (2) developing strong partnerships and collaborations to mitigate regulatory and competitive risks, (3) leveraging digital health technologies to enhance product development and commercialization, and (4) adapting to changing regulatory environments to ensure product approvals and market access."
        },
        "competitive_analysis": {
          "position": "Strong Player",
          "market_share_estimate": "Medium",
          "competitive_advantages": [
            "Established brand recognition in the Biotechnology industry",
            "Moderate scale advantages through manufacturing capabilities",
            "Revenue growth of 7.2% indicating a stable market presence"
          ],
          "competitive_disadvantages": [
            "Weak to Moderate competitive moat, making it vulnerable to new entrants",
            "Scalability score of 4.0/10 indicates limited ability to expand quickly"
          ],
          "differentiation_strategy": "Hybrid",
          "moat_strength": "Moderate",
          "scalability_assessment": "Low",
          "innovation_position": "Following",
          "brand_recognition": "Strong",
          "customer_loyalty": "Medium",
          "switching_costs": "Medium",
          "network_effects": "Weak"
        },
        "regulatory_analysis": {
          "risk_level": "Very High",
          "score": 8,
          "detailed_assessment": "The biotechnology sector is heavily regulated, with a high risk of non-compliance due to the complexity of regulations and the potential for severe consequences.",
          "key_regulations": [
            {
              "regulation": "Good Manufacturing Practice (GMP)",
              "impact": "Ensures the quality and safety of biotechnology products, including vaccines, therapeutics, and diagnostics.",
              "compliance_cost": "High",
              "timeline": "Ongoing, with regular inspections and audits."
            },
            {
              "regulation": "Clinical Trials Regulation (CTR)",
              "impact": "Regulates clinical trials, including ethics, informed consent, and data management.",
              "compliance_cost": "Medium",
              "timeline": "Implementation timeline: 2024-2026."
            },
            {
              "regulation": "General Data Protection Regulation (GDPR)",
              "impact": "Regulates data protection and privacy, including patient data and research data.",
              "compliance_cost": "Medium",
              "timeline": "Implementation timeline: 2018-2020."
            }
          ],
          "regulatory_trends": [
            {
              "trend": "Increasing scrutiny from regulatory bodies regarding data integrity, quality control, and patient safety.",
              "reasoning": "Regulatory bodies are responding to growing concerns about the quality and safety of biotechnology products.",
              "impact_on_industry": "The trend will lead to increased regulatory scrutiny, including more frequent inspections and audits.",
              "timeline": "Expected timeline: 2024-2026."
            }
          ],
          "compliance_burden": "High",
          "compliance_analysis": "CUV.AX must comply with a range of regulations, including GMP, CTR, and GDPR. Compliance requires significant resources, including personnel, training, and infrastructure.",
          "policy_risks": [
            {
              "risk": "Non-compliance with regulations",
              "probability": "High",
              "impact": "Potential for reputational damage and financial losses due to non-compliance or adverse events.",
              "mitigation": "Invest in compliance infrastructure, including personnel, training, and technology."
            }
          ],
          "regulatory_opportunities": [
            {
              "opportunity": "Emerging technologies and innovative products",
              "reasoning": "CUV.AX can leverage emerging technologies and innovative products to drive growth and competitiveness.",
              "timeline": "Expected timeline: 2024-2026.",
              "requirements": "Invest in research and development, and engage with regulatory bodies to understand emerging trends and requirements."
            }
          ],
          "upcoming_changes": [
            {
              "change": "Implementation of Clinical Trials Regulation (CTR)",
              "timeline": "Implementation timeline: 2024-2026.",
              "impact_analysis": "The CTR will lead to increased regulatory scrutiny, including more frequent inspections and audits.",
              "preparation_needed": "Invest in compliance infrastructure, including personnel, training, and technology."
            }
          ],
          "strategic_implications": "The regulatory environment presents both risks and opportunities for CUV.AX. To mitigate risks, the company must invest in compliance infrastructure, develop a robust quality management system, and engage with regulatory bodies. To leverage opportunities, CUV.AX should invest in research and development, and engage with regulatory bodies to understand emerging trends and requirements."
        },
        "esg_analysis": {
          "environmental_score": 6,
          "social_score": 7,
          "governance_score": 4,
          "overall_score": 5.67,
          "esg_risks": [
            "High governance risk",
            "Potential for environmental impact from medical waste and supply chain emissions"
          ],
          "esg_opportunities": [
            "Investing in sustainable medical supply chain practices",
            "Developing environmentally friendly medical products"
          ],
          "sustainability_trends": [
            "Increasing focus on environmental sustainability in healthcare",
            "Growing demand for eco-friendly medical products"
          ],
          "stakeholder_concerns": [
            "Patient safety and well-being",
            "Employee health and wellness"
          ]
        },
        "market_analysis": {
          "market_size": "Small",
          "estimated_market_value": 1900351360.0,
          "growth_rate": 0.072,
          "market_maturity": "Mature",
          "concentration": "Medium",
          "geographic_scope": "Regional"
        },
        "peer_benchmarks": {
          "avg_revenue_growth": 0.08,
          "avg_profit_margin": 0.12,
          "avg_roe": 0.15,
          "estimated_peers": 15
        },
        "key_risks": [
          "Regulatory approval risks",
          "Patent expiration",
          "Reimbursement changes",
          {
            "risk": "Non-compliance with regulations",
            "probability": "High",
            "impact": "Potential for reputational damage and financial losses due to non-compliance or adverse events.",
            "mitigation": "Invest in compliance infrastructure, including personnel, training, and technology."
          },
          "High governance risk",
          "Potential for environmental impact from medical waste and supply chain emissions"
        ],
        "analysis_type": "industry_analysis",
        "current_price": 12.64
      }
    },
    "final_recommendation": "Recommendation(ticker='CUV.AX', recommendation=<RecommendationType.BUY: 'Buy'>, confidence='Medium', target_price=np.float64(22.21605505747555), upside_potential=np.float64(75.75992925217999), risk_level='Low', bullish_signals=['MANAGEMENT_QUALITY indicates Buy', 'Technical: Strong Uptrend', 'DCF indicates Strong Buy', 'COMPARABLE indicates Strong Buy', 'INDUSTRY_ANALYSIS indicates Buy'], bearish_signals=[], key_risks=[], summary='Consensus: Buy | Confidence: Medium | Analyses: 10 | COMPETITIVE_POSITION: Hold | MANAGEMENT_QUALITY: Buy | ANALYST_CONSENSUS: Hold | TECHNICAL: Hold | DCF: Strong Buy | AI_INSIGHTS: Hold | COMPARABLE: Strong Buy | BUSINESS_MODEL: Hold | NEWS_SENTIMENT: Hold | INDUSTRY_ANALYSIS: Buy')",
    "analyst_comparison": {
      "comparisons": [
        "ComparisonResult(ticker='CUV.AX', method='analyst_consensus', our_price=24.53143, analyst_target=24.53143, current_price=12.64, our_upside=94.07776898734177, analyst_upside=94.07776898734177, deviation_score=0.0, alignment='Precise_Aligned', both_bullish=True, both_bearish=False, analyst_count=7)",
        "ComparisonResult(ticker='CUV.AX', method='technical', our_price=np.float64(18.081301080276063), analyst_target=24.53143, current_price=12.64, our_upside=np.float64(43.048268040158725), analyst_upside=94.07776898734177, deviation_score=np.float64(51.029500947183045), alignment='Directional_Aligned', both_bullish=True, both_bearish=np.False_, analyst_count=7)",
        "ComparisonResult(ticker='CUV.AX', method='dcf', our_price=np.float64(21.63923862417696), analyst_target=24.53143, current_price=12.64, our_upside=np.float64(71.19650810266582), analyst_upside=94.07776898734177, deviation_score=np.float64(22.881260884675953), alignment='Directional_Aligned', both_bullish=True, both_bearish=np.False_, analyst_count=7)",
        "ComparisonResult(ticker='CUV.AX', method='ai_insights', our_price=12.64, analyst_target=24.53143, current_price=12.64, our_upside=0.0, analyst_upside=94.07776898734177, deviation_score=94.07776898734177, alignment='Directional_Aligned', both_bullish=False, both_bearish=False, analyst_count=7)",
        "ComparisonResult(ticker='CUV.AX', method='comparable', our_price=30.32596369694949, analyst_target=24.53143, current_price=12.64, our_upside=139.92059886827127, analyst_upside=94.07776898734177, deviation_score=45.8428298809295, alignment='Directional_Aligned', both_bullish=True, both_bearish=False, analyst_count=7)"
      ],
      "summary": {
        "ai_insights": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 0,
          "alignment_rate": 100.0,
          "avg_deviation": 94.07776898734177
        },
        "dcf": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 22.881260884675953
        },
        "comparable": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 45.8428298809295
        },
        "analyst_consensus": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 0.0
        },
        "technical": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 51.029500947183045
        }
      }
    },
    "execution_time_seconds": 50.17,
    "analyses_count": 10
  },
  "PPL.AX": {
    "ticker": "PPL.AX",
    "company_type": "growth_profitable",
    "financial_metrics": {
      "market_cap": 54980452,
      "sector": "Communication Services",
      "industry": "Advertising Agencies",
      "fund_family": "",
      "category": "",
      "quote_type": "EQUITY",
      "long_name": "Pureprofile Ltd",
      "business_summary": "Pureprofile Ltd, a data and insights organization, engages in the provision of online research solutions for agencies, marketers, researchers, brands and businesses in Australasia, Europe, and the United States. The company conducts market research; and accesses insights and campaigns through its proprietary self-service platform. It also offers Audience Builder to create additional revenue streams and boost customer loyalty; Audience Intelligence, a data platform that offers insights into Australian consumer spending; and video surveys which provides qualitative research at a quantitative scale. In addition, the company provides Datarubico that offers self-serve data and insights solutions via an AI-enabled platform; synthetic responses; social insights tools; and Datarubico Sample Only, self-serve platform giving users access to sample sources. Further, it offers brand health services. Pureprofile Ltd was founded in 2000 and is headquartered in Surry Hills, Australia.",
      "enterprise_value": 53324868,
      "ev_ebitda_multiple": 27.756,
      "total_revenue": 57178132,
      "net_income": 1538778,
      "current_revenue": "$57,178,132.00",
      "yearly_revenue_growth": 0.16,
      "quarterly_revenue_growth": 0,
      "calculated_annual_growth": 18.949693196806603,
      "calculated_quarterly_growth": 0,
      "revenue_data_statements": {
        "quarterly_income_stmt": {},
        "annual_income_stmt": {
          "2025-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -1156.777509,
            "Tax Rate For Calcs": 0.031727,
            "Normalized EBITDA": 4748159.0,
            "Total Unusual Items": -36460.0,
            "Total Unusual Items Excluding Goodwill": -36460.0,
            "Net Income From Continuing Operation Net Minority Interest": 1538778.0,
            "Reconciled Depreciation": 2873717.0,
            "Reconciled Cost Of Revenue": 25713330.0,
            "EBITDA": 4711699.0,
            "EBIT": 1837982.0,
            "Net Interest Income": -373835.0,
            "Interest Expense": 248783.0,
            "Interest Income": 2169.0,
            "Normalized Income": 1574081.222491,
            "Net Income From Continuing And Discontinued Operation": 1538778.0,
            "Diluted Average Shares": NaN,
            "Basic Average Shares": NaN,
            "Diluted EPS": NaN,
            "Basic EPS": NaN,
            "Net Income Common Stockholders": 1538778.0,
            "Net Income": 1538778.0,
            "Net Income Including Noncontrolling Interests": 1538778.0,
            "Net Income Discontinuous Operations": NaN,
            "Net Income Continuous Operations": 1538778.0,
            "Tax Provision": 50421.0,
            "Pretax Income": 1589199.0,
            "Other Income Expense": 301018.0,
            "Other Non Operating Income Expenses": 337478.0,
            "Special Income Charges": -36460.0,
            "Gain On Sale Of Ppe": 4079.0,
            "Restructuring And Mergern Acquisition": 40539.0,
            "Net Non Operating Interest Income Expense": -373835.0,
            "Total Other Finance Cost": 127221.0,
            "Interest Expense Non Operating": 248783.0,
            "Interest Income Non Operating": 2169.0,
            "Operating Income": 1662016.0,
            "Operating Expense": 29802494.0,
            "Other Operating Expenses": 5133237.0,
            "Depreciation Amortization Depletion Income Statement": 2873717.0,
            "Depreciation And Amortization In Income Statement": 2873717.0,
            "Amortization": 2323446.0,
            "Amortization Of Intangibles Income Statement": 2323446.0,
            "Depreciation Income Statement": 550271.0,
            "Selling General And Administration": 21795540.0,
            "General And Administrative Expense": 21795540.0,
            "Rent And Landing Fees": 391387.0,
            "Salaries And Wages": 21404153.0,
            "Gross Profit": 31464510.0,
            "Cost Of Revenue": 25713330.0,
            "Total Revenue": 57177840.0,
            "Operating Revenue": 57177840.0
          },
          "2024-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -20538.152411,
            "Tax Rate For Calcs": 0.183956,
            "Normalized EBITDA": 3221061.0,
            "Total Unusual Items": -111647.0,
            "Total Unusual Items Excluding Goodwill": -111647.0,
            "Net Income From Continuing Operation Net Minority Interest": 107047.0,
            "Reconciled Depreciation": 2694344.0,
            "Reconciled Cost Of Revenue": 21399014.0,
            "EBITDA": 3109414.0,
            "EBIT": 415070.0,
            "Net Interest Income": -438890.0,
            "Interest Expense": 283892.0,
            "Interest Income": 518.0,
            "Normalized Income": 198155.847589,
            "Net Income From Continuing And Discontinued Operation": 94352.0,
            "Diluted Average Shares": 1149395879.0,
            "Basic Average Shares": 1149395879.0,
            "Diluted EPS": 0.0001,
            "Basic EPS": 0.0001,
            "Net Income Common Stockholders": 94352.0,
            "Net Income": 94352.0,
            "Net Income Including Noncontrolling Interests": 94352.0,
            "Net Income Discontinuous Operations": -12695.0,
            "Net Income Continuous Operations": 107047.0,
            "Tax Provision": 24131.0,
            "Pretax Income": 131178.0,
            "Other Income Expense": -142436.0,
            "Other Non Operating Income Expenses": -30789.0,
            "Special Income Charges": -111647.0,
            "Gain On Sale Of Ppe": 741.0,
            "Restructuring And Mergern Acquisition": 112388.0,
            "Net Non Operating Interest Income Expense": -438890.0,
            "Total Other Finance Cost": 155516.0,
            "Interest Expense Non Operating": 283892.0,
            "Interest Income Non Operating": 518.0,
            "Operating Income": 712504.0,
            "Operating Expense": 25957408.0,
            "Other Operating Expenses": 4619441.0,
            "Depreciation Amortization Depletion Income Statement": 2694344.0,
            "Depreciation And Amortization In Income Statement": 2694344.0,
            "Amortization": 2172178.0,
            "Amortization Of Intangibles Income Statement": 2172178.0,
            "Depreciation Income Statement": 522166.0,
            "Selling General And Administration": 18643623.0,
            "General And Administrative Expense": 18643623.0,
            "Rent And Landing Fees": 401756.0,
            "Salaries And Wages": 18241867.0,
            "Gross Profit": 26669912.0,
            "Cost Of Revenue": 21399014.0,
            "Total Revenue": 48068926.0,
            "Operating Revenue": 48068926.0
          },
          "2023-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -34024.2,
            "Tax Rate For Calcs": 0.3,
            "Normalized EBITDA": 2001187.0,
            "Total Unusual Items": -113414.0,
            "Total Unusual Items Excluding Goodwill": -113414.0,
            "Net Income From Continuing Operation Net Minority Interest": -1512904.0,
            "Reconciled Depreciation": 2952705.0,
            "Reconciled Cost Of Revenue": 19855763.0,
            "EBITDA": 1887773.0,
            "EBIT": -1064932.0,
            "Net Interest Income": -525927.0,
            "Interest Expense": 358110.0,
            "Interest Income": 157.0,
            "Normalized Income": -1433514.2,
            "Net Income From Continuing And Discontinued Operation": -2159208.0,
            "Diluted Average Shares": 1118994477.0,
            "Basic Average Shares": 1118994477.0,
            "Diluted EPS": -0.0019,
            "Basic EPS": -0.0019,
            "Net Income Common Stockholders": -2159208.0,
            "Net Income": -2159208.0,
            "Net Income Including Noncontrolling Interests": -2159208.0,
            "Net Income Discontinuous Operations": -646304.0,
            "Net Income Continuous Operations": -1512904.0,
            "Tax Provision": 89862.0,
            "Pretax Income": -1423042.0,
            "Other Income Expense": -145808.0,
            "Other Non Operating Income Expenses": -32394.0,
            "Special Income Charges": -113414.0,
            "Gain On Sale Of Ppe": 1558.0,
            "Restructuring And Mergern Acquisition": 114972.0,
            "Net Non Operating Interest Income Expense": -525927.0,
            "Total Other Finance Cost": 167974.0,
            "Interest Expense Non Operating": 358110.0,
            "Interest Income Non Operating": 157.0,
            "Operating Income": -751307.0,
            "Operating Expense": 24545246.0,
            "Other Operating Expenses": 4107841.0,
            "Depreciation Amortization Depletion Income Statement": 2952705.0,
            "Depreciation And Amortization In Income Statement": 2952705.0,
            "Amortization": 2470804.0,
            "Amortization Of Intangibles Income Statement": 2470804.0,
            "Depreciation Income Statement": 481901.0,
            "Selling General And Administration": 17484700.0,
            "General And Administrative Expense": 17484700.0,
            "Rent And Landing Fees": 325425.0,
            "Salaries And Wages": 17159275.0,
            "Gross Profit": 23793939.0,
            "Cost Of Revenue": 19855763.0,
            "Total Revenue": 43649702.0,
            "Operating Revenue": 43649702.0
          },
          "2022-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -10174.2,
            "Tax Rate For Calcs": 0.3,
            "Normalized EBITDA": 1563536.0,
            "Total Unusual Items": -33914.0,
            "Total Unusual Items Excluding Goodwill": -33914.0,
            "Net Income From Continuing Operation Net Minority Interest": -2164277.0,
            "Reconciled Depreciation": 3246427.0,
            "Reconciled Cost Of Revenue": 20182045.0,
            "EBITDA": 1529622.0,
            "EBIT": -1716805.0,
            "Net Interest Income": -496700.0,
            "Interest Expense": 351387.0,
            "Interest Income": NaN,
            "Normalized Income": -2140537.2,
            "Net Income From Continuing And Discontinued Operation": -2164277.0,
            "Diluted Average Shares": 1089228154.0,
            "Basic Average Shares": 1089228154.0,
            "Diluted EPS": -0.002,
            "Basic EPS": -0.002,
            "Net Income Common Stockholders": -2164277.0,
            "Net Income": -2164277.0,
            "Net Income Including Noncontrolling Interests": -2164277.0,
            "Net Income Discontinuous Operations": NaN,
            "Net Income Continuous Operations": -2164277.0,
            "Tax Provision": 96085.0,
            "Pretax Income": -2068192.0,
            "Other Income Expense": 583295.0,
            "Other Non Operating Income Expenses": 617209.0,
            "Special Income Charges": -33914.0,
            "Gain On Sale Of Ppe": -33914.0,
            "Restructuring And Mergern Acquisition": NaN,
            "Net Non Operating Interest Income Expense": -496700.0,
            "Total Other Finance Cost": 145313.0,
            "Interest Expense Non Operating": 351387.0,
            "Interest Income Non Operating": NaN,
            "Operating Income": -2154787.0,
            "Operating Expense": 23683711.0,
            "Other Operating Expenses": 5008861.0,
            "Depreciation Amortization Depletion Income Statement": 3246427.0,
            "Depreciation And Amortization In Income Statement": 3246427.0,
            "Amortization": 2687908.0,
            "Amortization Of Intangibles Income Statement": 2687908.0,
            "Depreciation Income Statement": 558519.0,
            "Selling General And Administration": 15428423.0,
            "General And Administrative Expense": 15428423.0,
            "Rent And Landing Fees": 141641.0,
            "Salaries And Wages": 15286782.0,
            "Gross Profit": 21528924.0,
            "Cost Of Revenue": 20182045.0,
            "Total Revenue": 41710969.0,
            "Operating Revenue": 41710969.0
          },
          "2021-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": NaN,
            "Tax Rate For Calcs": NaN,
            "Normalized EBITDA": NaN,
            "Total Unusual Items": NaN,
            "Total Unusual Items Excluding Goodwill": NaN,
            "Net Income From Continuing Operation Net Minority Interest": NaN,
            "Reconciled Depreciation": NaN,
            "Reconciled Cost Of Revenue": NaN,
            "EBITDA": NaN,
            "EBIT": NaN,
            "Net Interest Income": NaN,
            "Interest Expense": NaN,
            "Interest Income": 815.0,
            "Normalized Income": NaN,
            "Net Income From Continuing And Discontinued Operation": NaN,
            "Diluted Average Shares": 660151961.0,
            "Basic Average Shares": 660151961.0,
            "Diluted EPS": 0.0042,
            "Basic EPS": 0.0043,
            "Net Income Common Stockholders": NaN,
            "Net Income": NaN,
            "Net Income Including Noncontrolling Interests": NaN,
            "Net Income Discontinuous Operations": NaN,
            "Net Income Continuous Operations": NaN,
            "Tax Provision": NaN,
            "Pretax Income": NaN,
            "Other Income Expense": NaN,
            "Other Non Operating Income Expenses": NaN,
            "Special Income Charges": NaN,
            "Gain On Sale Of Ppe": NaN,
            "Restructuring And Mergern Acquisition": NaN,
            "Net Non Operating Interest Income Expense": NaN,
            "Total Other Finance Cost": NaN,
            "Interest Expense Non Operating": NaN,
            "Interest Income Non Operating": 815.0,
            "Operating Income": NaN,
            "Operating Expense": NaN,
            "Other Operating Expenses": NaN,
            "Depreciation Amortization Depletion Income Statement": NaN,
            "Depreciation And Amortization In Income Statement": NaN,
            "Amortization": NaN,
            "Amortization Of Intangibles Income Statement": NaN,
            "Depreciation Income Statement": NaN,
            "Selling General And Administration": NaN,
            "General And Administrative Expense": NaN,
            "Rent And Landing Fees": NaN,
            "Salaries And Wages": NaN,
            "Gross Profit": NaN,
            "Cost Of Revenue": NaN,
            "Total Revenue": NaN,
            "Operating Revenue": NaN
          }
        },
        "quarterly_financial_stmt": {},
        "annual_financial_stmt": {
          "2025-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -1156.777509,
            "Tax Rate For Calcs": 0.031727,
            "Normalized EBITDA": 4748159.0,
            "Total Unusual Items": -36460.0,
            "Total Unusual Items Excluding Goodwill": -36460.0,
            "Net Income From Continuing Operation Net Minority Interest": 1538778.0,
            "Reconciled Depreciation": 2873717.0,
            "Reconciled Cost Of Revenue": 25713330.0,
            "EBITDA": 4711699.0,
            "EBIT": 1837982.0,
            "Net Interest Income": -373835.0,
            "Interest Expense": 248783.0,
            "Interest Income": 2169.0,
            "Normalized Income": 1574081.222491,
            "Net Income From Continuing And Discontinued Operation": 1538778.0,
            "Diluted Average Shares": NaN,
            "Basic Average Shares": NaN,
            "Diluted EPS": NaN,
            "Basic EPS": NaN,
            "Net Income Common Stockholders": 1538778.0,
            "Net Income": 1538778.0,
            "Net Income Including Noncontrolling Interests": 1538778.0,
            "Net Income Discontinuous Operations": NaN,
            "Net Income Continuous Operations": 1538778.0,
            "Tax Provision": 50421.0,
            "Pretax Income": 1589199.0,
            "Other Income Expense": 301018.0,
            "Other Non Operating Income Expenses": 337478.0,
            "Special Income Charges": -36460.0,
            "Gain On Sale Of Ppe": 4079.0,
            "Restructuring And Mergern Acquisition": 40539.0,
            "Net Non Operating Interest Income Expense": -373835.0,
            "Total Other Finance Cost": 127221.0,
            "Interest Expense Non Operating": 248783.0,
            "Interest Income Non Operating": 2169.0,
            "Operating Income": 1662016.0,
            "Operating Expense": 29802494.0,
            "Other Operating Expenses": 5133237.0,
            "Depreciation Amortization Depletion Income Statement": 2873717.0,
            "Depreciation And Amortization In Income Statement": 2873717.0,
            "Amortization": 2323446.0,
            "Amortization Of Intangibles Income Statement": 2323446.0,
            "Depreciation Income Statement": 550271.0,
            "Selling General And Administration": 21795540.0,
            "General And Administrative Expense": 21795540.0,
            "Rent And Landing Fees": 391387.0,
            "Salaries And Wages": 21404153.0,
            "Gross Profit": 31464510.0,
            "Cost Of Revenue": 25713330.0,
            "Total Revenue": 57177840.0,
            "Operating Revenue": 57177840.0
          },
          "2024-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -20538.152411,
            "Tax Rate For Calcs": 0.183956,
            "Normalized EBITDA": 3221061.0,
            "Total Unusual Items": -111647.0,
            "Total Unusual Items Excluding Goodwill": -111647.0,
            "Net Income From Continuing Operation Net Minority Interest": 107047.0,
            "Reconciled Depreciation": 2694344.0,
            "Reconciled Cost Of Revenue": 21399014.0,
            "EBITDA": 3109414.0,
            "EBIT": 415070.0,
            "Net Interest Income": -438890.0,
            "Interest Expense": 283892.0,
            "Interest Income": 518.0,
            "Normalized Income": 198155.847589,
            "Net Income From Continuing And Discontinued Operation": 94352.0,
            "Diluted Average Shares": 1149395879.0,
            "Basic Average Shares": 1149395879.0,
            "Diluted EPS": 0.0001,
            "Basic EPS": 0.0001,
            "Net Income Common Stockholders": 94352.0,
            "Net Income": 94352.0,
            "Net Income Including Noncontrolling Interests": 94352.0,
            "Net Income Discontinuous Operations": -12695.0,
            "Net Income Continuous Operations": 107047.0,
            "Tax Provision": 24131.0,
            "Pretax Income": 131178.0,
            "Other Income Expense": -142436.0,
            "Other Non Operating Income Expenses": -30789.0,
            "Special Income Charges": -111647.0,
            "Gain On Sale Of Ppe": 741.0,
            "Restructuring And Mergern Acquisition": 112388.0,
            "Net Non Operating Interest Income Expense": -438890.0,
            "Total Other Finance Cost": 155516.0,
            "Interest Expense Non Operating": 283892.0,
            "Interest Income Non Operating": 518.0,
            "Operating Income": 712504.0,
            "Operating Expense": 25957408.0,
            "Other Operating Expenses": 4619441.0,
            "Depreciation Amortization Depletion Income Statement": 2694344.0,
            "Depreciation And Amortization In Income Statement": 2694344.0,
            "Amortization": 2172178.0,
            "Amortization Of Intangibles Income Statement": 2172178.0,
            "Depreciation Income Statement": 522166.0,
            "Selling General And Administration": 18643623.0,
            "General And Administrative Expense": 18643623.0,
            "Rent And Landing Fees": 401756.0,
            "Salaries And Wages": 18241867.0,
            "Gross Profit": 26669912.0,
            "Cost Of Revenue": 21399014.0,
            "Total Revenue": 48068926.0,
            "Operating Revenue": 48068926.0
          },
          "2023-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -34024.2,
            "Tax Rate For Calcs": 0.3,
            "Normalized EBITDA": 2001187.0,
            "Total Unusual Items": -113414.0,
            "Total Unusual Items Excluding Goodwill": -113414.0,
            "Net Income From Continuing Operation Net Minority Interest": -1512904.0,
            "Reconciled Depreciation": 2952705.0,
            "Reconciled Cost Of Revenue": 19855763.0,
            "EBITDA": 1887773.0,
            "EBIT": -1064932.0,
            "Net Interest Income": -525927.0,
            "Interest Expense": 358110.0,
            "Interest Income": 157.0,
            "Normalized Income": -1433514.2,
            "Net Income From Continuing And Discontinued Operation": -2159208.0,
            "Diluted Average Shares": 1118994477.0,
            "Basic Average Shares": 1118994477.0,
            "Diluted EPS": -0.0019,
            "Basic EPS": -0.0019,
            "Net Income Common Stockholders": -2159208.0,
            "Net Income": -2159208.0,
            "Net Income Including Noncontrolling Interests": -2159208.0,
            "Net Income Discontinuous Operations": -646304.0,
            "Net Income Continuous Operations": -1512904.0,
            "Tax Provision": 89862.0,
            "Pretax Income": -1423042.0,
            "Other Income Expense": -145808.0,
            "Other Non Operating Income Expenses": -32394.0,
            "Special Income Charges": -113414.0,
            "Gain On Sale Of Ppe": 1558.0,
            "Restructuring And Mergern Acquisition": 114972.0,
            "Net Non Operating Interest Income Expense": -525927.0,
            "Total Other Finance Cost": 167974.0,
            "Interest Expense Non Operating": 358110.0,
            "Interest Income Non Operating": 157.0,
            "Operating Income": -751307.0,
            "Operating Expense": 24545246.0,
            "Other Operating Expenses": 4107841.0,
            "Depreciation Amortization Depletion Income Statement": 2952705.0,
            "Depreciation And Amortization In Income Statement": 2952705.0,
            "Amortization": 2470804.0,
            "Amortization Of Intangibles Income Statement": 2470804.0,
            "Depreciation Income Statement": 481901.0,
            "Selling General And Administration": 17484700.0,
            "General And Administrative Expense": 17484700.0,
            "Rent And Landing Fees": 325425.0,
            "Salaries And Wages": 17159275.0,
            "Gross Profit": 23793939.0,
            "Cost Of Revenue": 19855763.0,
            "Total Revenue": 43649702.0,
            "Operating Revenue": 43649702.0
          },
          "2022-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": -10174.2,
            "Tax Rate For Calcs": 0.3,
            "Normalized EBITDA": 1563536.0,
            "Total Unusual Items": -33914.0,
            "Total Unusual Items Excluding Goodwill": -33914.0,
            "Net Income From Continuing Operation Net Minority Interest": -2164277.0,
            "Reconciled Depreciation": 3246427.0,
            "Reconciled Cost Of Revenue": 20182045.0,
            "EBITDA": 1529622.0,
            "EBIT": -1716805.0,
            "Net Interest Income": -496700.0,
            "Interest Expense": 351387.0,
            "Interest Income": NaN,
            "Normalized Income": -2140537.2,
            "Net Income From Continuing And Discontinued Operation": -2164277.0,
            "Diluted Average Shares": 1089228154.0,
            "Basic Average Shares": 1089228154.0,
            "Diluted EPS": -0.002,
            "Basic EPS": -0.002,
            "Net Income Common Stockholders": -2164277.0,
            "Net Income": -2164277.0,
            "Net Income Including Noncontrolling Interests": -2164277.0,
            "Net Income Discontinuous Operations": NaN,
            "Net Income Continuous Operations": -2164277.0,
            "Tax Provision": 96085.0,
            "Pretax Income": -2068192.0,
            "Other Income Expense": 583295.0,
            "Other Non Operating Income Expenses": 617209.0,
            "Special Income Charges": -33914.0,
            "Gain On Sale Of Ppe": -33914.0,
            "Restructuring And Mergern Acquisition": NaN,
            "Net Non Operating Interest Income Expense": -496700.0,
            "Total Other Finance Cost": 145313.0,
            "Interest Expense Non Operating": 351387.0,
            "Interest Income Non Operating": NaN,
            "Operating Income": -2154787.0,
            "Operating Expense": 23683711.0,
            "Other Operating Expenses": 5008861.0,
            "Depreciation Amortization Depletion Income Statement": 3246427.0,
            "Depreciation And Amortization In Income Statement": 3246427.0,
            "Amortization": 2687908.0,
            "Amortization Of Intangibles Income Statement": 2687908.0,
            "Depreciation Income Statement": 558519.0,
            "Selling General And Administration": 15428423.0,
            "General And Administrative Expense": 15428423.0,
            "Rent And Landing Fees": 141641.0,
            "Salaries And Wages": 15286782.0,
            "Gross Profit": 21528924.0,
            "Cost Of Revenue": 20182045.0,
            "Total Revenue": 41710969.0,
            "Operating Revenue": 41710969.0
          },
          "2021-06-30 00:00:00": {
            "Tax Effect Of Unusual Items": NaN,
            "Tax Rate For Calcs": NaN,
            "Normalized EBITDA": NaN,
            "Total Unusual Items": NaN,
            "Total Unusual Items Excluding Goodwill": NaN,
            "Net Income From Continuing Operation Net Minority Interest": NaN,
            "Reconciled Depreciation": NaN,
            "Reconciled Cost Of Revenue": NaN,
            "EBITDA": NaN,
            "EBIT": NaN,
            "Net Interest Income": NaN,
            "Interest Expense": NaN,
            "Interest Income": 815.0,
            "Normalized Income": NaN,
            "Net Income From Continuing And Discontinued Operation": NaN,
            "Diluted Average Shares": 660151961.0,
            "Basic Average Shares": 660151961.0,
            "Diluted EPS": 0.0042,
            "Basic EPS": 0.0043,
            "Net Income Common Stockholders": NaN,
            "Net Income": NaN,
            "Net Income Including Noncontrolling Interests": NaN,
            "Net Income Discontinuous Operations": NaN,
            "Net Income Continuous Operations": NaN,
            "Tax Provision": NaN,
            "Pretax Income": NaN,
            "Other Income Expense": NaN,
            "Other Non Operating Income Expenses": NaN,
            "Special Income Charges": NaN,
            "Gain On Sale Of Ppe": NaN,
            "Restructuring And Mergern Acquisition": NaN,
            "Net Non Operating Interest Income Expense": NaN,
            "Total Other Finance Cost": NaN,
            "Interest Expense Non Operating": NaN,
            "Interest Income Non Operating": 815.0,
            "Operating Income": NaN,
            "Operating Expense": NaN,
            "Other Operating Expenses": NaN,
            "Depreciation Amortization Depletion Income Statement": NaN,
            "Depreciation And Amortization In Income Statement": NaN,
            "Amortization": NaN,
            "Amortization Of Intangibles Income Statement": NaN,
            "Depreciation Income Statement": NaN,
            "Selling General And Administration": NaN,
            "General And Administrative Expense": NaN,
            "Rent And Landing Fees": NaN,
            "Salaries And Wages": NaN,
            "Gross Profit": NaN,
            "Cost Of Revenue": NaN,
            "Total Revenue": NaN,
            "Operating Revenue": NaN
          }
        },
        "cashflow": {
          "2025-06-30 00:00:00": {
            "Free Cash Flow": 2360592.0,
            "Repurchase Of Capital Stock": NaN,
            "Repayment Of Debt": -200000.0,
            "Issuance Of Capital Stock": 98602.0,
            "Capital Expenditure": -2429990.0,
            "Interest Paid Supplemental Data": 250204.0,
            "Income Tax Paid Supplemental Data": 67565.0,
            "End Cash Position": 5722836.0,
            "Beginning Cash Position": 5237973.0,
            "Effect Of Exchange Rate Changes": 16875.0,
            "Changes In Cash": 467988.0,
            "Financing Cash Flow": -606144.0,
            "Cash Flow From Continuing Financing Activities": -606144.0,
            "Net Other Financing Charges": -504746.0,
            "Net Common Stock Issuance": 98602.0,
            "Common Stock Payments": NaN,
            "Common Stock Issuance": 98602.0,
            "Net Issuance Payments Of Debt": -200000.0,
            "Net Long Term Debt Issuance": -200000.0,
            "Long Term Debt Payments": -200000.0,
            "Investing Cash Flow": -3716450.0,
            "Cash Flow From Continuing Investing Activities": -3716450.0,
            "Net Business Purchase And Sale": -1290539.0,
            "Purchase Of Business": -1290539.0,
            "Net Intangibles Purchase And Sale": -2269866.0,
            "Purchase Of Intangibles": -2269866.0,
            "Net PPE Purchase And Sale": -156045.0,
            "Sale Of PPE": 4079.0,
            "Purchase Of PPE": -160124.0,
            "Cash Flowsfromusedin Operating Activities Direct": 4790582.0,
            "Taxes Refund Paid Direct": -67565.0,
            "Interest Received Direct": 2169.0,
            "Interest Paid Direct": -250204.0,
            "Classesof Cash Payments": -51734273.0,
            "Paymentsto Suppliersfor Goodsand Services": -51734273.0,
            "Classesof Cash Receiptsfrom Operating Activities": 56840455.0,
            "Receiptsfrom Government Grants": NaN,
            "Receiptsfrom Customers": 56840455.0
          },
          "2024-06-30 00:00:00": {
            "Free Cash Flow": 1189743.0,
            "Repurchase Of Capital Stock": NaN,
            "Repayment Of Debt": -100000.0,
            "Issuance Of Capital Stock": NaN,
            "Capital Expenditure": -2303500.0,
            "Interest Paid Supplemental Data": 438298.0,
            "Income Tax Paid Supplemental Data": 85966.0,
            "End Cash Position": 5237973.0,
            "Beginning Cash Position": 4726460.0,
            "Effect Of Exchange Rate Changes": -6237.0,
            "Changes In Cash": 517750.0,
            "Financing Cash Flow": -632941.0,
            "Cash Flow From Continuing Financing Activities": -632941.0,
            "Net Other Financing Charges": -532941.0,
            "Net Common Stock Issuance": NaN,
            "Common Stock Payments": NaN,
            "Common Stock Issuance": NaN,
            "Net Issuance Payments Of Debt": -100000.0,
            "Net Long Term Debt Issuance": -100000.0,
            "Long Term Debt Payments": -100000.0,
            "Investing Cash Flow": -2342552.0,
            "Cash Flow From Continuing Investing Activities": -2342552.0,
            "Net Business Purchase And Sale": -39793.0,
            "Purchase Of Business": -39793.0,
            "Net Intangibles Purchase And Sale": -2236921.0,
            "Purchase Of Intangibles": -2236921.0,
            "Net PPE Purchase And Sale": -65838.0,
            "Sale Of PPE": 741.0,
            "Purchase Of PPE": -66579.0,
            "Cash Flowsfromusedin Operating Activities Direct": 3493243.0,
            "Taxes Refund Paid Direct": -85966.0,
            "Interest Received Direct": 518.0,
            "Interest Paid Direct": -438298.0,
            "Classesof Cash Payments": -44169929.0,
            "Paymentsto Suppliersfor Goodsand Services": -44169929.0,
            "Classesof Cash Receiptsfrom Operating Activities": 48186918.0,
            "Receiptsfrom Government Grants": NaN,
            "Receiptsfrom Customers": 48186918.0
          },
          "2023-06-30 00:00:00": {
            "Free Cash Flow": 33193.0,
            "Repurchase Of Capital Stock": NaN,
            "Repayment Of Debt": NaN,
            "Issuance Of Capital Stock": 15000.0,
            "Capital Expenditure": -2535499.0,
            "Interest Paid Supplemental Data": 270610.0,
            "Income Tax Paid Supplemental Data": 91027.0,
            "End Cash Position": 4726460.0,
            "Beginning Cash Position": 5298389.0,
            "Effect Of Exchange Rate Changes": 31787.0,
            "Changes In Cash": -603716.0,
            "Financing Cash Flow": -521937.0,
            "Cash Flow From Continuing Financing Activities": -521937.0,
            "Net Other Financing Charges": -536937.0,
            "Net Common Stock Issuance": 15000.0,
            "Common Stock Payments": NaN,
            "Common Stock Issuance": 15000.0,
            "Net Issuance Payments Of Debt": NaN,
            "Net Long Term Debt Issuance": NaN,
            "Long Term Debt Payments": NaN,
            "Investing Cash Flow": -2650471.0,
            "Cash Flow From Continuing Investing Activities": -2650471.0,
            "Net Business Purchase And Sale": -114972.0,
            "Purchase Of Business": -114972.0,
            "Net Intangibles Purchase And Sale": -2392708.0,
            "Purchase Of Intangibles": -2392708.0,
            "Net PPE Purchase And Sale": -142791.0,
            "Sale Of PPE": NaN,
            "Purchase Of PPE": -142791.0,
            "Cash Flowsfromusedin Operating Activities Direct": 2568692.0,
            "Taxes Refund Paid Direct": -91027.0,
            "Interest Received Direct": 157.0,
            "Interest Paid Direct": -270610.0,
            "Classesof Cash Payments": -45760364.0,
            "Paymentsto Suppliersfor Goodsand Services": -45760364.0,
            "Classesof Cash Receiptsfrom Operating Activities": 48690536.0,
            "Receiptsfrom Government Grants": NaN,
            "Receiptsfrom Customers": 48690536.0
          },
          "2022-06-30 00:00:00": {
            "Free Cash Flow": 1621944.0,
            "Repurchase Of Capital Stock": NaN,
            "Repayment Of Debt": NaN,
            "Issuance Of Capital Stock": 534000.0,
            "Capital Expenditure": -2269818.0,
            "Interest Paid Supplemental Data": 263887.0,
            "Income Tax Paid Supplemental Data": 94742.0,
            "End Cash Position": 5298389.0,
            "Beginning Cash Position": 3621675.0,
            "Effect Of Exchange Rate Changes": -30006.0,
            "Changes In Cash": 1706720.0,
            "Financing Cash Flow": 80571.0,
            "Cash Flow From Continuing Financing Activities": 80571.0,
            "Net Other Financing Charges": -906858.0,
            "Net Common Stock Issuance": 534000.0,
            "Common Stock Payments": NaN,
            "Common Stock Issuance": 534000.0,
            "Net Issuance Payments Of Debt": NaN,
            "Net Long Term Debt Issuance": NaN,
            "Long Term Debt Payments": NaN,
            "Investing Cash Flow": -2265613.0,
            "Cash Flow From Continuing Investing Activities": -2265613.0,
            "Net Business Purchase And Sale": NaN,
            "Purchase Of Business": NaN,
            "Net Intangibles Purchase And Sale": -2217326.0,
            "Purchase Of Intangibles": -2217326.0,
            "Net PPE Purchase And Sale": -48287.0,
            "Sale Of PPE": 4205.0,
            "Purchase Of PPE": -52492.0,
            "Cash Flowsfromusedin Operating Activities Direct": 3891762.0,
            "Taxes Refund Paid Direct": -94742.0,
            "Interest Received Direct": NaN,
            "Interest Paid Direct": -263887.0,
            "Classesof Cash Payments": -39113843.0,
            "Paymentsto Suppliersfor Goodsand Services": -39113843.0,
            "Classesof Cash Receiptsfrom Operating Activities": 43364234.0,
            "Receiptsfrom Government Grants": NaN,
            "Receiptsfrom Customers": 43364234.0
          },
          "2021-06-30 00:00:00": {
            "Free Cash Flow": NaN,
            "Repurchase Of Capital Stock": -1080749.0,
            "Repayment Of Debt": -9896878.0,
            "Issuance Of Capital Stock": 13396878.0,
            "Capital Expenditure": NaN,
            "Interest Paid Supplemental Data": NaN,
            "Income Tax Paid Supplemental Data": NaN,
            "End Cash Position": NaN,
            "Beginning Cash Position": NaN,
            "Effect Of Exchange Rate Changes": NaN,
            "Changes In Cash": NaN,
            "Financing Cash Flow": NaN,
            "Cash Flow From Continuing Financing Activities": NaN,
            "Net Other Financing Charges": NaN,
            "Net Common Stock Issuance": 12316129.0,
            "Common Stock Payments": -1080749.0,
            "Common Stock Issuance": 13396878.0,
            "Net Issuance Payments Of Debt": -9896878.0,
            "Net Long Term Debt Issuance": -9896878.0,
            "Long Term Debt Payments": -9896878.0,
            "Investing Cash Flow": NaN,
            "Cash Flow From Continuing Investing Activities": NaN,
            "Net Business Purchase And Sale": NaN,
            "Purchase Of Business": NaN,
            "Net Intangibles Purchase And Sale": NaN,
            "Purchase Of Intangibles": NaN,
            "Net PPE Purchase And Sale": NaN,
            "Sale Of PPE": 8841.0,
            "Purchase Of PPE": NaN,
            "Cash Flowsfromusedin Operating Activities Direct": NaN,
            "Taxes Refund Paid Direct": NaN,
            "Interest Received Direct": 815.0,
            "Interest Paid Direct": NaN,
            "Classesof Cash Payments": NaN,
            "Paymentsto Suppliersfor Goodsand Services": NaN,
            "Classesof Cash Receiptsfrom Operating Activities": NaN,
            "Receiptsfrom Government Grants": 478500.0,
            "Receiptsfrom Customers": NaN
          }
        },
        "annual_revenue": {
          "2025-06-30 00:00:00": 57177840.0,
          "2024-06-30 00:00:00": 48068926.0,
          "2023-06-30 00:00:00": 43649702.0,
          "2022-06-30 00:00:00": 41710969.0
        },
        "recent_annual_growth": 18.949693196806603,
        "current_revenue": 57178132,
        "revenue_growth": 0.16,
        "quarterly_revenue_growth": 0
      },
      "free_cash_flow": 2360592.0,
      "total_debt": 4095456,
      "total_cash": 5722836,
      "shares_outstanding": 1169796802,
      "current_price": 0.047,
      "beta": 0.447,
      "pe_ratio": "Infinity",
      "pb_ratio": 7.833333,
      "ps_ratio": 0.9615643,
      "peg_ratio": null,
      "roe": 0.23871,
      "roa": 0.037130002,
      "debt_to_equity": 0.55701,
      "current_ratio": 1.13,
      "revenue_growth": 0.16,
      "earnings_growth": null,
      "dividend_yield": null,
      "payout_ratio": 0.0,
      "profit_margin": 2.691,
      "quick_ratio": 1.058,
      "book_value_per_share": 0.006,
      "cash_per_share": 0.005,
      "fifty_two_week_high": 0.054,
      "fifty_two_week_low": 0.03
    },
    "quality_score": {
      "error": "'>' not supported between instances of 'str' and 'int'"
    },
    "analyses": {
      "competitive_position": {
        "method": "Competitive Position Analysis",
        "applicable": true,
        "overall_position_score": 5.8,
        "competitive_strength": "Moderate",
        "market_share_estimate": 0.01,
        "position_trend": "Strengthening",
        "key_differentiators": [
          "Superior Profitability"
        ],
        "competitive_advantages": [
          "Financial Performance"
        ],
        "competitive_threats": [],
        "strategic_risks": [
          "High Leverage Risk"
        ],
        "confidence": "Medium",
        "recommendation": "Hold",
        "analysis_type": "competitive_position",
        "current_price": 0.047
      },
      "technical": {
        "method": "Technical Analysis",
        "current_price": 0.047,
        "predicted_price": 0.07501337630967432,
        "price_targets": {
          "short_term": 0.06450835959004943,
          "medium_term": 0.08201672078942426,
          "support_level": 0.028499999362975356
        },
        "recommendation": "Strong Buy",
        "ma_20": 0.04620000030845404,
        "ma_50": 0.046899999976158145,
        "ma_200": 0.04290250014513731,
        "trend": "Strong Uptrend",
        "volatility_annual": 0.7450366722926833,
        "high_52w": 0.05400000140070915,
        "low_52w": 0.029999999329447746,
        "distance_from_high": -0.1296296820085385,
        "distance_from_low": 0.5666666480402147,
        "volume_trend": "Average Daily Volume:1498544.0472440945, Trend: Below Average",
        "rsi_14": 52.30978684895554,
        "macd_line": 0.0002990479738602808,
        "macd_signal": 6.916231812192533e-05,
        "macd_histogram": 0.00022988565573835547,
        "bb_upper": 0.048922226869863535,
        "bb_lower": 0.04347777374704454,
        "stoch_k": 55.555534859501726,
        "stoch_d": 61.11110076308419,
        "technical_signals": {
          "recommendation": "Strong Buy",
          "bullish_signals": 6,
          "bearish_signals": 1,
          "net_signal": 5,
          "signal_details": [
            "Strong MA uptrend",
            "RSI bearish zone",
            "MACD bullish crossover",
            "MACD histogram positive"
          ]
        },
        "chart_data": {
          "prices": [
            0.04600000008940697,
            0.04699999839067459,
            0.04600000008940697,
            0.04600000008940697,
            0.04699999839067459,
            0.04500000178813934,
            0.04500000178813934,
            0.04500000178813934,
            0.04500000178813934,
            0.04500000178813934,
            0.04600000008940697,
            0.04399999976158142,
            0.04500000178813934,
            0.04500000178813934,
            0.04899999871850014,
            0.04800000041723251,
            0.04800000041723251,
            0.04800000041723251,
            0.04699999839067459,
            0.04699999839067459
          ],
          "dates": [
            "12/09",
            "12/10",
            "12/11",
            "12/12",
            "12/15",
            "12/16",
            "12/17",
            "12/18",
            "12/19",
            "12/22",
            "12/23",
            "12/24",
            "12/29",
            "12/30",
            "12/31",
            "01/02",
            "01/05",
            "01/06",
            "01/07",
            "01/08"
          ]
        },
        "analysis_type": "technical"
      },
      "comparable": {
        "method": "Comparable Analysis",
        "applicable": true,
        "target_multiples": {
          "pe": 16.2,
          "ps": 2.25,
          "pb": 1.8,
          "ev_ebitda": 10.8
        },
        "fair_values": {
          "pe_fair_value": 0.021309857880770645,
          "ps_fair_value": 0.10997704625285853
        },
        "predicted_price": 0.06564345206681459,
        "current_price": 0.047,
        "upside_downside_pct": 39.666919291094864,
        "recommendation": "Strong Buy",
        "confidence": "Medium",
        "sector": "Communication Services",
        "industry": "Advertising Agencies",
        "parameters_used": {
          "pe_multiple": "16.2x",
          "ps_multiple": "2.2x",
          "quality_adjustment": "C"
        },
        "analysis_type": "comparable"
      },
      "analyst_consensus": {
        "method": "Professional Analyst Consensus",
        "applicable": true,
        "current_price": 0.047,
        "predicted_price": 0.11,
        "target_high": 0.11,
        "target_low": 0.11,
        "upside_downside_pct": 134.04255319148936,
        "recommendation": "Hold",
        "recommendation_mean": null,
        "num_analysts": 1,
        "confidence": "Low",
        "analysis_type": "analyst_consensus"
      },
      "management_quality": {
        "method": "Management Quality Analysis",
        "applicable": true,
        "overall_quality_score": 6.5,
        "management_quality": "Good",
        "governance_risk": "Medium",
        "executive_count": 5,
        "insider_ownership": 0.37893,
        "strengths": [
          "Strong financial performance under current management"
        ],
        "concerns": [],
        "key_insights": [
          "Leadership team of 5 key executives identified",
          "Average executive compensation: $743,354"
        ],
        "confidence": "Medium",
        "recommendation": "Buy",
        "analysis_type": "management_quality",
        "current_price": 0.047
      },
      "dcf": {
        "method": "DCF Analysis",
        "applicable": true,
        "predicted_price": 0.07559406228532498,
        "current_price": 0.047,
        "upside_downside_pct": 60.83843039430846,
        "total_equity_value": 88429692.31156197,
        "confidence": "Medium",
        "valuation": "Undervalued",
        "recommendation": "Strong Buy",
        "dcf_calculations": {
          "wacc": 0.053353513786038635,
          "cost_equity": 0.058869870000000005,
          "ev_ebitda_multiple": 27.756,
          "ev_ebitda_multiple_used": 10.8,
          "fcf_cagr": 0.07200000000000001,
          "ebitda_cagr": 0.07200000000000001,
          "fcf_future": 3341910.830306657,
          "ebitda_future": 6670393.6627952,
          "terminal_value_pg": 120812490.01141548,
          "terminal_value_ebitda_multiple": 72040251.55818817,
          "average_terminal_value": 96426370.78480183,
          "adjusted_terminal_value": 96426370.78480183,
          "terminal_adjustment_factor": 1.0,
          "projected_free_cash_flows": [
            2530554.6240000003,
            2712754.5569280004,
            2908072.8850268167,
            3117454.1327487477,
            3341910.830306657
          ],
          "present_value_free_cash_flows": [
            2402379.249587823,
            2444906.2179530193,
            2488185.999613053,
            2532231.9208848183,
            2577057.543987949
          ],
          "pv_fcf": 12444760.932026662,
          "pv_terminal_value": 74357551.3795353,
          "enterprise_value": 86802312.31156197,
          "adjusted_debt": -1627380,
          "equity_value": 88429692.31156197,
          "share_price": 0.07559406228532498,
          "ticker_symbol": "PPL.AX",
          "last_close_price": 0.047,
          "confidence": "Medium",
          "terminal_ratio": 0.8856927384166886
        },
        "parameters_used": {
          "max_cagr": "7.2%",
          "terminal_growth": "2.5%",
          "sector": "Communication Services",
          "industry": "Advertising Agencies",
          "quality_adjustment": "C",
          "valuation_discount": null
        },
        "analysis_type": "dcf"
      },
      "ai_insights": {
        "method": "AI Insights Analysis",
        "applicable": true,
        "current_price": 0.047,
        "predicted_price": 0.054049999999999994,
        "recommendation": "Buy",
        "confidence": "High",
        "ai_insights": {
          "market_position": "Moderate",
          "growth_prospects": "High",
          "competitive_advantage": "Moderate",
          "management_quality": "Good",
          "industry_outlook": "Positive",
          "key_strengths": [
            "High revenue growth rate of 16.0%, indicating a strong ability to expand its customer base and increase sales",
            "Strong return on equity (ROE) of 23.9%, suggesting effective management of shareholder funds and a high level of profitability"
          ],
          "key_risks": [
            "Dependence on the advertising industry, which can be highly competitive and subject to economic fluctuations",
            "Potential disruption from changes in consumer behavior, technological advancements, or shifts in marketing strategies, which could impact the company's ability to adapt and maintain its market position"
          ],
          "ai_method": "LLM"
        },
        "revenue_trends": {
          "trend_assessment": "Strong Growth",
          "growth_rate": 16.0,
          "growth_consistency": "Consistent",
          "future_outlook": "Very Positive",
          "ai_method": "LLM"
        },
        "market_analysis": {
          "market_cap_category": "Micro Cap",
          "sector": "Communication Services",
          "industry": "Advertising Agencies",
          "beta": 0.447
        },
        "ai_methods_used": {
          "insights": "LLM",
          "revenue_trends": "LLM"
        },
        "risk_factors": [],
        "analysis_type": "ai_insights"
      },
      "business_model": {
        "method": "Business Model Analysis",
        "applicable": true,
        "business_model_type": "Advertising Based",
        "primary_revenue_stream": "Mixed",
        "revenue_quality": "Good",
        "recurring_percentage": 0.0,
        "scalability_score": 7.5,
        "growth_consistency": null,
        "strengths": [
          "High cross-selling potential enhances customer lifetime value"
        ],
        "risks": [
          "Low recurring revenue creates earnings volatility",
          "Competitive threat: Increasing competition from new market entrants with innovative technologies",
          "Competitive threat: Changing client preferences and evolving market trends"
        ],
        "competitive_moat": "Weak to Moderate - Scale and data advantages",
        "confidence": "Medium",
        "recommendation": "Buy",
        "product_portfolio": {
          "product_breadth": "Moderate",
          "product_depth": "Moderate",
          "core_products": [
            "Data Analytics",
            "Market Research",
            "Digital Advertising"
          ],
          "innovation_level": "Moderate",
          "cross_selling_potential": "High",
          "product_strengths": [
            "Targeted Advertising Capabilities",
            "Data-Driven Insights"
          ],
          "product_weaknesses": [
            "Dependence on Client Relationships",
            "Intense Competition in Advertising Industry"
          ],
          "data_source": "LLM Analysis Only"
        },
        "competitive_differentiation": {
          "differentiation_strategy": "Differentiation",
          "competitive_advantages": [
            "Specialized data analytics capabilities",
            "Strong market research expertise",
            "Ability to provide targeted digital advertising solutions"
          ],
          "unique_value_propositions": [
            "Providing actionable insights to clients through data-driven market research",
            "Offering personalized digital advertising solutions to enhance client engagement"
          ],
          "key_competitors": [
            "Nielsen Holdings",
            "comScore",
            "Experian"
          ],
          "competitive_positioning": "Challenger",
          "barriers_to_entry": [
            "High upfront costs for developing advanced data analytics capabilities",
            "Established relationships between clients and existing market research firms"
          ],
          "switching_costs": "Moderate",
          "brand_strength": "Moderate",
          "technology_moat": "Moderate",
          "distribution_advantages": [
            "Strategic partnerships with key industry players",
            "Global reach through online platforms"
          ],
          "competitive_threats": [
            "Increasing competition from new market entrants with innovative technologies",
            "Changing client preferences and evolving market trends"
          ]
        },
        "segment_revenue_data": {
          "primary_segments": [
            {
              "segment_name": "Data and Insights",
              "revenue_percentage": 60.0,
              "growth_trend": "Growing",
              "margin_profile": "Medium"
            },
            {
              "segment_name": "Media and Advertising",
              "revenue_percentage": 30.0,
              "growth_trend": "Stable",
              "margin_profile": "Low"
            },
            {
              "segment_name": "Platform and Software",
              "revenue_percentage": 10.0,
              "growth_trend": "Growing",
              "margin_profile": "High"
            }
          ],
          "revenue_diversification": "Medium",
          "fastest_growing_segment": "Platform and Software",
          "largest_segment": "Data and Insights",
          "segment_risks": [
            "Dependence on key clients",
            "Intense competition in the advertising industry",
            "Regulatory risks related to data privacy"
          ],
          "cross_segment_synergies": [
            "Integration of data and insights with media and advertising services",
            "Development of platform and software solutions to support data-driven advertising"
          ]
        },
        "sec_edgar_data": {
          "ticker": "PPL.AX",
          "data_available": false
        },
        "analysis_type": "business_model",
        "current_price": 0.047
      },
      "news_sentiment": {
        "method": "News Sentiment Analysis",
        "applicable": true,
        "overall_sentiment_score": 0.13999999999999999,
        "sentiment_rating": "Neutral",
        "news_count": 5,
        "recent_news": [
          {
            "title": "ASX Penny Stocks To Watch In January 2026",
            "summary": "As the Australian share market faces its first downturn of the year, with futures suggesting only a slight dip, investors are keeping a close eye on potential opportunities amid fluctuating global sentiments. Penny stocks, often associated with smaller or newer companies, remain an intriguing investment area despite being considered somewhat outdated. These stocks can offer unique growth prospects at lower price points when backed by strong financial health and solid fundamentals. In this...",
            "date": "2026-01-08",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/asx-penny-stocks-watch-january-030513567.html",
            "sentiment": "neutral",
            "sentiment_score": 0.0,
            "enhanced_facts": {
              "lead_fact": "Australian share market faces its first downturn of the year",
              "quantitative_evidence": "None",
              "business_mechanism": "Potential impact on investor sentiment and market volatility for PPL.AX",
              "verbatim_quote": "None"
            }
          },
          {
            "title": "Top 3 ASX Penny Stocks With Market Caps Over A$50M",
            "summary": "As the Australian market shows resilience with a cooler-than-expected inflation read, investors are closely watching potential moves by the Reserve Bank of Australia. In such a climate, penny stocks can offer intriguing opportunities for those willing to explore beyond established names. Despite being an older term, penny stocks\u2014often smaller or newer companies\u2014remain relevant as they can provide affordability and growth potential when backed by strong financials.",
            "date": "2026-01-07",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/top-3-asx-penny-stocks-200242373.html",
            "sentiment": "neutral",
            "sentiment_score": 0.2,
            "enhanced_facts": {
              "lead_fact": "Australian market shows resilience with a cooler-than-expected inflation read",
              "quantitative_evidence": "Market Caps Over A$50M",
              "business_mechanism": "Potential moves by the Reserve Bank of Australia could impact penny stocks like PPL.AX",
              "verbatim_quote": "penny stocks can offer intriguing opportunities for those willing to explore beyond established names"
            }
          },
          {
            "title": "Exploring High Growth Tech Stocks in Australia Featuring Three Prominent Companies",
            "summary": "As the Australian market edges towards the holiday season, it is experiencing a slight dip, largely attributed to profit-taking as major global indices approach record highs. In this context, high growth tech stocks in Australia can offer intriguing opportunities for investors seeking innovation and potential expansion, particularly when these companies demonstrate resilience and adaptability amidst fluctuating economic conditions.",
            "date": "2025-12-30",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-193612686.html",
            "sentiment": "neutral",
            "sentiment_score": 0.0,
            "enhanced_facts": {
              "lead_fact": "Australian market experiencing a slight dip due to profit-taking",
              "quantitative_evidence": "None",
              "business_mechanism": "No direct impact on PPL.AX's business mentioned in the article",
              "verbatim_quote": "None"
            }
          },
          {
            "title": "Exploring 3 High Growth Tech Stocks in Australia",
            "summary": "As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact small-cap stocks. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate these fluctuations effectively while capitalizing on technological advancements and strategic opportunities in the sector.",
            "date": "2025-12-07",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-193533873.html",
            "sentiment": "neutral",
            "sentiment_score": 0.0,
            "enhanced_facts": {
              "lead_fact": "Australian market experiences a tentative rise",
              "quantitative_evidence": "None",
              "business_mechanism": "Potential impact on small-cap stocks, including PPL.AX, due to fluctuations in the market",
              "verbatim_quote": "None"
            }
          },
          {
            "title": "ASX Penny Stocks Spotlight: BKI Investment And 2 Other Noteworthy Picks",
            "summary": "The Australian stock market is experiencing a surge, with shares poised for a significant leap following a tech rally in New York, sparking bullish sentiment. Penny stocks, often overlooked and considered relics of past trading days, still hold potential for growth by offering investors access to smaller or newer companies at lower price points. By focusing on those with strong financials and clear growth paths, investors can uncover hidden gems that might offer both stability and upside...",
            "date": "2025-11-26",
            "source": "Simply Wall St.",
            "url": "https://finance.yahoo.com/news/asx-penny-stocks-spotlight-bki-030515408.html",
            "sentiment": "neutral",
            "sentiment_score": 0.5,
            "enhanced_facts": {
              "lead_fact": "Australian stock market surge following a tech rally in New York",
              "quantitative_evidence": "None",
              "business_mechanism": "Potential for growth in smaller or newer companies, including PPL.AX, due to increased bullish sentiment",
              "verbatim_quote": "None"
            }
          }
        ],
        "key_developments": [],
        "sentiment_drivers": [
          "Positive coverage in 1 recent news items"
        ],
        "risk_factors": [],
        "overall_summary": [
          "The overall sentiment score of 0.14 indicates a slightly positive outlook, driven by a few articles with higher sentiment scores, such as the ASX Penny Stocks Spotlight with a score of 0.50, which highlights noteworthy picks and potential investment opportunities",
          "However, the majority of the articles have a neutral sentiment score of 0.00, suggesting a cautious or neutral market reaction to the ASX penny stocks and high growth tech stocks, with no strong positive or negative trends emerging",
          "The presence of articles with higher sentiment scores, such as the Top 3 ASX Penny Stocks With Market Caps Over A$50M, suggests that some investors are optimistic about the potential for growth in certain sectors, which contributes to the slightly positive overall sentiment score",
          "Despite the slightly positive sentiment, the overall score of 0.14 remains relatively low, indicating that investors and market analysts are approaching the ASX penny stocks and high growth tech stocks with caution, and are waiting for more concrete developments or trends to emerge before making more decisive investments"
        ],
        "confidence": "Medium",
        "recommendation": "Hold",
        "analysis_type": "news_sentiment",
        "current_price": 0.047
      },
      "industry_analysis": {
        "method": "Enhanced Industry Analysis",
        "applicable": true,
        "sector": "Communication Services",
        "industry": "Advertising Agencies",
        "recommendation": "Buy",
        "confidence": "Medium",
        "predicted_price": null,
        "industry_outlook": "Neutral",
        "competitive_position": "Strong Player",
        "market_catalysts": [
          "**1. Increased Focus on Data Protection (Regulatory/Policy, Ongoing)**",
          "**2. Growing Importance of Online Advertising Transparency (Regulatory/Policy, Ongoing)**",
          "**3. Implementation of new data protection regulations (Regulatory/Policy, Ongoing)**",
          "**4. Shift to Digital Advertising (Market/Economic, Ongoing)**",
          "**5. Consolidation in the Advertising Industry (Industry-specific, Ongoing)**",
          "**6. Growing Importance of Sustainability in Advertising (ESG/Sustainability, Ongoing)**",
          "**7. Adoption of Artificial Intelligence (AI) in Advertising (Technology/Innovation, Ongoing)**"
        ],
        "porters_five_forces": {
          "supplier_power": {
            "level": "Medium",
            "factors": [
              "Standard suppliers"
            ],
            "score": 5
          },
          "buyer_power": {
            "level": "Medium",
            "factors": [
              "Diverse customers"
            ],
            "score": 5
          },
          "competitive_rivalry": {
            "level": "Medium",
            "factors": [
              "Industry competition"
            ],
            "score": 5
          },
          "threat_of_substitutes": {
            "level": "Medium",
            "factors": [
              "Alternative solutions"
            ],
            "score": 5
          },
          "barriers_to_entry": {
            "level": "Medium",
            "factors": [
              "Capital requirements"
            ],
            "score": 5
          },
          "overall_attractiveness": "Medium",
          "industry_profitability_outlook": "Stable"
        },
        "regulatory_risk": "Very High",
        "esg_score": 7,
        "market_size_estimate": "Small",
        "industry_growth_rate": 0.16,
        "industry_insights": {
          "outlook": "Neutral",
          "growth_drivers": [
            "Market expansion",
            "Innovation"
          ],
          "headwinds": [
            "Competition",
            "Regulation"
          ],
          "market_size": "Medium",
          "maturity": "Mature",
          "cyclicality": "Medium",
          "regulatory_environment": "Neutral",
          "technology_disruption": "Medium",
          "supply_demand_balance": "Balanced"
        },
        "competitive_analysis": {
          "position": "Strong Player",
          "market_share_estimate": "Medium",
          "competitive_advantages": [
            "Data-driven advertising strategies",
            "Strong relationships with clients and media partners",
            "Moderate scale advantages in the Australian market"
          ],
          "competitive_disadvantages": [
            "Limited global presence and scale compared to international competitors",
            "Dependence on a few key clients and revenue streams"
          ],
          "differentiation_strategy": "Hybrid (Cost Leadership and Differentiation)",
          "moat_strength": "Moderate",
          "scalability_assessment": "Medium",
          "innovation_position": "Following",
          "brand_recognition": "Average",
          "customer_loyalty": "Medium",
          "switching_costs": "Medium",
          "network_effects": "Moderate"
        },
        "regulatory_analysis": {
          "risk_level": "Very High",
          "score": 8,
          "detailed_assessment": "The regulatory environment for Advertising Agencies is complex and rapidly evolving.",
          "key_regulations": [
            {
              "regulation": "Australian Consumer Law (ACL)",
              "impact": "Regulates advertising practices, including truth in advertising, product safety, and consumer rights.",
              "compliance_cost": "High",
              "timeline": "Already implemented"
            },
            {
              "regulation": "Australian Privacy Act 1988",
              "impact": "Regulates the collection, storage, and use of personal data.",
              "compliance_cost": "High",
              "timeline": "Already implemented"
            },
            {
              "regulation": "Australian Competition and Consumer Commission (ACCC) Guidelines",
              "impact": "Provides guidelines for advertising and marketing practices.",
              "compliance_cost": "Medium",
              "timeline": "Ongoing"
            },
            {
              "regulation": "Australian Communications and Media Authority (ACMA) Regulations",
              "impact": "Regulates online content, including advertising.",
              "compliance_cost": "Medium",
              "timeline": "Ongoing"
            },
            {
              "regulation": "General Data Protection Regulation (GDPR)",
              "impact": "Influences global data protection regulations.",
              "compliance_cost": "High",
              "timeline": "Ongoing"
            }
          ],
          "regulatory_trends": [
            {
              "trend": "Increased Focus on Data Protection",
              "reasoning": "The GDPR and other regulations emphasize data protection and consumer rights.",
              "impact_on_industry": "High compliance cost, High timeline (ongoing)",
              "timeline": "Ongoing"
            },
            {
              "trend": "Growing Importance of Online Advertising Transparency",
              "reasoning": "Regulators are scrutinizing online advertising practices, including ad targeting and data collection.",
              "impact_on_industry": "Medium compliance cost, Medium timeline (ongoing)",
              "timeline": "Ongoing"
            },
            {
              "trend": "Rise of Digital Platforms and Influencers",
              "reasoning": "The increasing influence of digital platforms and influencers creates new regulatory challenges.",
              "impact_on_industry": "Medium compliance cost, Low timeline (ongoing)",
              "timeline": "Ongoing"
            }
          ],
          "compliance_burden": "High",
          "compliance_analysis": "PPL.AX must comply with various regulations, including the ACL, Privacy Act, ACCC Guidelines, and ACMA Regulations.",
          "policy_risks": [
            {
              "risk": "Non-compliance with regulations",
              "probability": "High",
              "impact": "Potential fines or reputational damage",
              "mitigation": "Staff training, policy development, and ongoing monitoring"
            }
          ],
          "regulatory_opportunities": [
            {
              "opportunity": "Innovative advertising practices",
              "reasoning": "Regulations shape the types of advertising practices that are acceptable.",
              "timeline": "Ongoing",
              "requirements": "Staff training, policy development, and ongoing monitoring"
            }
          ],
          "upcoming_changes": [
            {
              "change": "Implementation of new data protection regulations",
              "timeline": "Ongoing",
              "impact_analysis": "Potential high compliance cost, High timeline (ongoing)",
              "preparation_needed": "Staff training, policy development, and ongoing monitoring"
            }
          ],
          "strategic_implications": "Regulations affect competitive positioning by influencing advertising practices, affecting data collection and use, and shaping industry standards."
        },
        "esg_analysis": {
          "environmental_score": 6,
          "social_score": 7,
          "governance_score": 8,
          "overall_score": 7,
          "esg_risks": [
            "Cybersecurity risks due to increasing digitalization",
            "Dependence on raw materials and supply chain disruptions"
          ],
          "esg_opportunities": [
            "Investing in renewable energy sources to reduce carbon footprint",
            "Developing digital services to enhance customer experience"
          ],
          "sustainability_trends": [
            "Growing demand for 5G and IoT technologies",
            "Increasing focus on digital literacy and online safety"
          ],
          "stakeholder_concerns": [
            "Customer data protection and privacy",
            "Employee well-being and work-life balance in a rapidly changing industry"
          ]
        },
        "market_analysis": {
          "market_size": "Small",
          "estimated_market_value": 1143562640.0,
          "growth_rate": 0.16,
          "market_maturity": "Growth",
          "concentration": "Medium",
          "geographic_scope": "Regional"
        },
        "peer_benchmarks": {
          "avg_revenue_growth": 0.08,
          "avg_profit_margin": 0.12,
          "avg_roe": 0.15,
          "estimated_peers": 15
        },
        "key_risks": [
          "Regulatory scrutiny",
          "Technology disruption",
          "Content costs",
          {
            "risk": "Non-compliance with regulations",
            "probability": "High",
            "impact": "Potential fines or reputational damage",
            "mitigation": "Staff training, policy development, and ongoing monitoring"
          },
          "Cybersecurity risks due to increasing digitalization",
          "Dependence on raw materials and supply chain disruptions"
        ],
        "analysis_type": "industry_analysis",
        "current_price": 0.047
      }
    },
    "final_recommendation": "Recommendation(ticker='PPL.AX', recommendation=<RecommendationType.BUY: 'Buy'>, confidence='High', target_price=np.float64(0.07888671243114533), upside_potential=np.float64(67.84406900243685), risk_level='Medium', bullish_signals=['TECHNICAL indicates Strong Buy', 'Technical: Strong Uptrend', 'COMPARABLE indicates Strong Buy', 'MANAGEMENT_QUALITY indicates Buy', 'DCF indicates Strong Buy', 'AI_INSIGHTS indicates Buy', 'BUSINESS_MODEL indicates Buy', 'INDUSTRY_ANALYSIS indicates Buy'], bearish_signals=[], key_risks=['High volatility', 'Low confidence in analyst_consensus analysis'], summary='Consensus: Buy | Confidence: High | Analyses: 10 | COMPETITIVE_POSITION: Hold | TECHNICAL: Strong Buy | COMPARABLE: Strong Buy | ANALYST_CONSENSUS: Hold | MANAGEMENT_QUALITY: Buy | DCF: Strong Buy | AI_INSIGHTS: Buy | BUSINESS_MODEL: Buy | NEWS_SENTIMENT: Hold | INDUSTRY_ANALYSIS: Buy')",
    "analyst_comparison": {
      "comparisons": [
        "ComparisonResult(ticker='PPL.AX', method='technical', our_price=np.float64(0.07501337630967432), analyst_target=0.11, current_price=0.047, our_upside=np.float64(59.60292831845601), analyst_upside=134.04255319148936, deviation_score=np.float64(74.43962487303335), alignment='Directional_Aligned', both_bullish=True, both_bearish=np.False_, analyst_count=1)",
        "ComparisonResult(ticker='PPL.AX', method='comparable', our_price=0.06564345206681459, analyst_target=0.11, current_price=0.047, our_upside=39.666919291094864, analyst_upside=134.04255319148936, deviation_score=94.37563390039449, alignment='Directional_Aligned', both_bullish=True, both_bearish=False, analyst_count=1)",
        "ComparisonResult(ticker='PPL.AX', method='analyst_consensus', our_price=0.11, analyst_target=0.11, current_price=0.047, our_upside=134.04255319148936, analyst_upside=134.04255319148936, deviation_score=0.0, alignment='Precise_Aligned', both_bullish=True, both_bearish=False, analyst_count=1)",
        "ComparisonResult(ticker='PPL.AX', method='dcf', our_price=np.float64(0.07559406228532498), analyst_target=0.11, current_price=0.047, our_upside=np.float64(60.83843039430846), analyst_upside=134.04255319148936, deviation_score=np.float64(73.2041227971809), alignment='Directional_Aligned', both_bullish=True, both_bearish=np.False_, analyst_count=1)",
        "ComparisonResult(ticker='PPL.AX', method='ai_insights', our_price=0.054049999999999994, analyst_target=0.11, current_price=0.047, our_upside=14.999999999999986, analyst_upside=134.04255319148936, deviation_score=119.04255319148938, alignment='Directional_Aligned', both_bullish=True, both_bearish=False, analyst_count=1)"
      ],
      "summary": {
        "ai_insights": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 119.04255319148938
        },
        "dcf": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 73.2041227971809
        },
        "comparable": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 94.37563390039449
        },
        "analyst_consensus": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 0.0
        },
        "technical": {
          "total_comparisons": 1,
          "aligned_count": 1,
          "bullish_convergent": 1,
          "alignment_rate": 100.0,
          "avg_deviation": 74.43962487303335
        }
      }
    },
    "execution_time_seconds": 44.59,
    "analyses_count": 10
  }
}